
Participating Company Profiles

Accera, Inc.....	2	Great Basin Scientific, Inc.....	29
Acucela, Inc.....	3	Helixis, Inc.....	30
Adnavance Technologies (US), Inc.....	4	HemaQuest Pharmaceuticals, Inc.....	31
Advinus Therapeutics Pvt. Ltd.....	5	ImmunoVaccine Technologies Inc.....	32
Akebia Therapeutics, Inc.....	6	Japan Tobacco, Inc.....	33
Altor Bioscience Corporation.....	7	Kinex Pharmaceuticals, LLC.....	34
Anthera Pharmaceuticals, Inc.....	8	Kyorin USA, Inc.....	35
Arisaph Pharmaceuticals, LLC.....	9	LineaGen, Inc.....	36
Ascent Therapeutics, Inc.....	10	Merck & Co., Inc.....	37
Axial Biotech, Inc.....	11	Mirna Therapeutics Inc.....	38
Biopremiere Inc.....	12	Mithridion, Inc.....	39
BioRelix, Inc.....	13	Nanotherapeutics, Inc.....	40
Boehringer Ingelheim GmbH.....	14	NeurAxon, Inc.....	41
Calistoga Pharmaceuticals, Inc.....	15	NeuroHealing Pharmaceuticals, Inc.....	42
Catena Pharmaceuticals, Inc.....	16	Nupotential, Inc.....	43
Celtaxsys, Inc.....	17	Oncolix, Inc.....	44
Centrose, LLC.....	18	ParinGenix, Inc.....	45
Cequent Pharmaceuticals, Inc.....	19	Profectus BioSciences, Inc.....	46
Critical Biologics Corporation.....	20	Resolvix Pharmaceuticals, Inc.....	47
Cynvec LLC.....	21	Stemina Biomarker Discovery, Inc.....	48
Cytox Limited.....	22	Targepeutics, Inc.....	49
DiaKine Therapeutics, Inc.....	23	Tetraphase Pharmaceuticals, Inc.....	50
Dicerna Pharmaceuticals, Inc.....	24	Teva Pharmaceuticals USA, Inc.....	51
EnzymeRx LLC.....	25	Topaz Pharmaceuticals, Inc.....	52
FluGen, Inc.....	26	TyrogeneX.....	53
FORMA Therapeutics, Inc.....	27	Viron Therapeutics, Inc.....	54
GliaMed, Inc.....	28	Vitreoretinal Technologies, Inc.....	55

Accera, Inc.

CNS

Steve Orndorff, PhD

President & CEO

380 Interlocken Crescent
Broomfield, CO 80021
USA

www.accerapharma.com

1 (303) 999-3700

Incorporated: 2001

Employees: 65

Ownership: Private

HIGHLIGHTS

Recent

Accera was founded in 2001 and has raised ~\$50 million in venture financing to date. Accera recently closed a \$35 million Series-C equity financing in 4Q08, which is being used for commercialization of Axona in the US.

Upcoming

Successfully commercialize Axona for the treatment of Alzheimer's disease in the US in 1Q09.

Successfully partner Axona ex-US in 2009

CORPORATE MISSION

We bring innovative therapeutic approaches to major unmet medical needs.

PROPRIETARY TECHNOLOGY

Accera has developed a new approach to the treatment of neurodegenerative diseases based upon the observed phenomenon of defective energy metabolism in the brain. The company has successfully completed three human clinical trials and a pioneering clinical study in canines that demonstrate the efficacy of our lead compound, Axona™, and its' mechanism-of-action in neuronal cells.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
Axona (caprylidene)	On Market	Alzheimer's Disease
AC-8632	Preclinical	Parkinson's Disease
AC-0523	Preclinical	Diseases of the nervous system

SENIOR MANAGEMENT

Steve Orndorff, PhD, President & CEO • **Samuel Henderson, PhD**, Other • **Greg Kading, CFA, MBA**, Vice President • **William Poncy, MBA**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): September 2004 (6.00 million) • August 2006 (7.50 million)

Acucela, Inc.

Ophthalmic

Ryo Kubota, MD, PhD

President & CEO

21720 23rd Drive SE
Bothell, WA 98021
USA

www.acucela.com

1 (425) 527-3260

Incorporated: 2002

Employees: 22

Ownership: Private

HIGHLIGHTS

Recent

Signed Co-Development & Commercialization Agreement with Otsuka Pharmaceutical Co., Ltd. for the lead compound ACU-4429 which is currently in Phase I clinical development for the dry form of age-related macular degeneration (AMD) in the United States.

Signed Co-Development Agreement with Otsuka Pharmaceutical Co., Ltd. for Rebamipide ophthalmic suspension which is Otsuka's proprietary compound for the treatment of dry eye which is currently in Phase III clinical development in the United States.

Upcoming

Initiate Phase 2 clinical trial, 3Q09

CORPORATE MISSION

Developing new drug therapies for blinding eye diseases such as age-related macular degeneration (AMD), Stargardt disease, diabetic retinopathy and retinopathy of prematurity, as well as dry eye.

PROPRIETARY TECHNOLOGY

Our VCM (Visual Cycle Modulation) compounds have demonstrated the ability to slow the visual cycle in clinical and preclinical studies in multiple eye diseases including AMD. Modulating the visual cycle has been shown to protect the retina from light damage, and to reduce the accumulation of retinal related toxic by-products such as A2E which is implicated in AMD.

CORPORATE ALLIANCES

Otsuka Pharmaceutical Co., Ltd.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
ACU-4429	Phase I	Dry AMD
Rebamipide	Phase III	Dry eye

SENIOR MANAGEMENT

Ryo Kubota, MD, PhD, President & CEO

Adnavance Technologies (US), Inc.

Infectious Disease

Randy White, PhD Chief Executive Officer

11494 Sorrento Valley Road, Suite H
San Diego, CA 92121
USA

www.adnavance.com

1 (858) 523-9250

Incorporated: 2007

Ownership: Private

HIGHLIGHTS

Recent

July 2008 – meets development milestone for direct detection MRSA diagnostic test and triggers \$1.8 million in second tranche of series B financing.

May 2008 – appoints Christian Valcke to its Scientific Advisory Board.

March 2008 – appoints Ron Sosnowski VP R&D and opens San Diego facility.

Upcoming

Report sensitivity, specificity and reproducibility for MRSA working assay.

Enter into first strategic partnering agreement.

Complete Series C round of financing.

CORPORATE MISSION

Adnavance's mission is to de-centralize the \$3.5 billion worldwide molecular diagnostic testing market and enable any laboratory to perform these important medical tests.

Adnavance develops direct detection molecular diagnostic tests. The goal for its proprietary M-DNA technology is to open the \$3 billion DNA diagnostics market to all laboratories. In the U.S., fewer than 1,000 of the 8,700 total hospitals are licensed to perform DNA-based tests, and only 15,000 of the approximately 36,000 independent laboratories can perform the testing. Thus, Adnavance's technology could open the DNA diagnostic market to over 30,000 new customers.

PROPRIETARY TECHNOLOGY

The company's patented M-DNA technology simplifies DNA-based testing by eliminating the PCR amplification step. The metallization step allows the ultra-sensitive detection of specific sequences or mutations in a background of competing DNA sequences.

CORPORATE ALLIANCES

The company is actively seeking alliances for strategic development and collaboration and is currently engaged in one negotiation for a strategic collaboration agreement.

PRODUCTS

<u>Name</u>	<u>Phase</u>	<u>Indication</u>	<u>Milestone</u>
MRSA (Methicillin Resistant Staph Aureus)	Diagnostics	Acute infection / Hospital admission screening	Launch early 2010
Factor V Leiden/Factor II and Warfarin SNP's	Diagnostics	Abnormal clotting and therapeutic dosing for Coumadin	
HPV Speciation of High Risk Serotypes	Diagnostics	Triage patients infected with high-risk HPV	
Cystic Fibrosis - 32 mutations	Diagnostics	General population carrier screening	

SENIOR MANAGEMENT

Randy White, PhD, Chief Executive Officer • **Gene Dantsker, PhD**, Chief Technology Officer • **Ron Sosnowski, PhD**, Vice President • **Marcelo Baru, MS**, Director

FINANCING HISTORY

Round Date (Amount, US\$): February 2008 (2.9 million)

Investors: JOVInvestment Management • Growthworks Venture Capital • Business Development Bank of Canada (BDC)

Advinus Therapeutics Pvt. Ltd.

Drug Development • Drug Discovery • Chemistry

Rashmi Barbhैया Chief Executive Officer

21&22 Phase II Peenya Industrial Area,
Bangalore 560058
India

www.advinus.com

91 (80) 2839-4959

Incorporated: 2005

Employees: 500

Ownership: Private

HIGHLIGHTS

Recent

Advinus has completed many INDs for U.S. large pharma and leading biotechnology companies, which can be carried out at 50% of the U.S. cost. The data from these INDs has been accepted by the FDA and the EMEA.

Drug discovery alliance with Merck & Co. for the discovery and development of new molecules for the treatment of metabolic diseases.

We have created a Pharmaceutical Development Services R&D facility with over 370 professionals in less than 3 years since the company's founding in 2005.

We are providing many IND Package and Carci studies to client companies.

Upcoming

We have recently tripled the size of our drug discovery facility.

Advinus is a major R&D player in India in the discovery and development of new drugs for a variety of Neglected Diseases.

CORPORATE MISSION

Advinus is an R&D driven company focused on the new drug discovery and development of pharmaceutical and agrochemical products.

We aim -

- To be the leading discovery organization in India as judged by the quality of its leadership and people, discovery programs, partnerships, productivity through INDs and successful out-licensing. "Pipeline is our lifeline".
- To be the first choice pharmaceutical services provider in India, by offering innovative solutions and comprehensive services in the development value chain.
- To leverage the India advantage whilst maintaining global quality and speed.

CORPORATE ALLIANCES

Alliance with Merck and Co. Inc. for discovery and development of NMEs for treatment of metabolic diseases.

Alliance with J&J for the discovery and development of innovative NME drugs.

Alliance with DNDi for discovery and development of new drugs for the treatment of visceral leishmaniasis (Kala Azar).

SENIOR MANAGEMENT

Rashmi Barbhैया, Chief Executive Officer • **Nimish Vachharajani**, Chief Scientific Officer • **Kasim Mookhtiar**, Chief Technology Officer
• **Rajiv Malik**, Chief Business Officer • **Eric Nelson**, Business Development

FINANCING HISTORY

Investors:

The Tata Group and Private Investors including the CEO

Akebia Therapeutics, Inc.

Hematology • Drug Development • Cardiovascular Disease

Joseph Gardner Chief Executive Officer

10151 Carver Road
Cincinnati, OH 45242
USA

www.akebia.com

1 (513) 618-0931

Incorporated: 2007

Employees: 8

Ownership: Private

HIGHLIGHTS

Recent

Akebia's anemia drug has shown good oral bioavailability in rodents and dogs, and has produced large increases in hemoglobin and hematocrit. We have completed GLP toxicity testing in rats and dogs.

Akebia's human protein tyrosine phosphatase beta inhibitor has demonstrated robust animal proof-of concept data for vascular growth in multiple models and for protection against vascular leak.

Upcoming

Enter Phase 1 clinical testing in July 2009

Complete preclinical GLP toxicity testing by January 2010

CORPORATE MISSION

Akebia's goal is to in-license and develop breakthrough small molecule drugs that deliver significant therapeutic benefit for the treatment of anemia and vascular disease.

PROPRIETARY TECHNOLOGY

Our HIF prolyl hydroxylase inhibitor is an orally available small molecule that increases the body's natural production of erythropoietin (EPO) in anemic patients in a more cost effective and safe manner than recombinant EPO. Our protein tyrosine phosphatase inhibitor is a small molecule that will promote angiogenesis in vascular disease and provide vascular stabilization against vascular leak.

CORPORATE ALLIANCES

Akebia has established collaborations with renowned centers of research such as the Cleveland Clinic as well as collaborations with researchers in several universities such as the University of Chicago, University of California at San Diego, The Medical College of Wisconsin, and others.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
AKEB-6548	Preclinical	anemia	Enter Phase 1 July 2009
AKEB-9778	Preclinical	vascular disease	Complete GLP toxicity testing January 2010

SENIOR MANAGEMENT

Joseph Gardner, Chief Executive Officer • **Robert Shalwitz**, Chief Medical Officer

FINANCING HISTORY

Round Date (Amount, US\$): May 2007 (1.0 million) • January 2008 (10.4 million)

Investors: **Triathlon Medical Ventures** (19%) • **Novartis Venture Funds** (15%) • **Kearny Venture Partners** (15%) • **Athenian Venture Partners** (10%) • **Venture Investors** (15%)

Altor Bioscience Corporation

Biopharmaceuticals • Oncology • Infectious Disease

Hing C. Wong, PhD

President & CEO

2810 North Commerce Pkwy
Miramar, FL 33025
USA

www.althorbioscience.com

1 (954) 443-8600

Incorporated: 2002

Employees: 21

Ownership: Private

HIGHLIGHTS

Recent

Initiated FDA-approved Phase II clinical study of ALT-836, anti-tissue factor antibody, in patients with Acute Respiratory Distress Syndrome/Acute Lung Injury.

Awarded grant from the Gates Foundation under the Grand Challenges Explorations program to engineer single-chain TCRs to target HIV-infected cells for immunotherapy. Awarded 2 SBIR grants from NIH for TCR-based approaches for cancer and HIV infection.

Upcoming

2Q09 - Complete Phase I/IIa clinical study of ALT-801 in patients with metastatic p53+ malignancies.

2Q09 - Initiate Phase I clinical study of ALT-801 with NK cell infusion in patients with AML.

CORPORATE MISSION

Altor BioScience Corporation is a venture-backed, clinical-stage, biopharmaceutical company engaged principally in the discovery, development and commercialization of high-value, targeted immunotherapeutic agents for the treatment of cancer, viral infections and immune diseases. Altor's STAR™ technology platform is founded on unique skills that facilitate the rapid manipulation and development of soluble T-cell receptor (TCR) as next-generation disease targeting agents. Using this technology, Altor is focused on improving the safety and efficacy of existing drugs for patients with cancer and viral infection. Altor has adopted a clinical development strategy of evaluating its drug candidates in their approved indications in order to minimize risk and facilitate rapid progress in clinical trials. Altor has secured its position with both a strong intellectual property portfolio and a pipeline of promising drug candidates. Altor currently has three products in clinical development. Its lead product, STAR™ -Ck or ALT-801, an anti-cancer drug, is currently enrolling patients in a Phase I/IIa clinical trial at four renowned cancer research centers in the U.S. A second product, which prevents and treats staphylococcal infections in premature neonates, has been out-licensed to Biosynexus and is now beginning a Phase III trial. The company's third product, an antibody-based Tissue Factor antagonist originally developed by Sunol, has been recently in-licensed from Genentech and is entering a multi-center Phase II trial in Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI). Management believes the total U.S. market opportunity for all of Altor's products and indications exceeds \$20 billion.

CORPORATE ALLIANCES

Biosynexus:Out-licensed therapeutics for staphylococcal infection; Genentech:In-licensed anti-tissue factor antagonist for inflammatory disease; Scripps:In-licensed p53-specific TCR technology; Mass. General Hospital:In-licensed TCR technology for HIV and Hepatitis C; National Institute of Health:In-licensed TCR technology for tumor antigens, Collaboration on discovery/development of anti-HIV TCR.

PRODUCTS

Name	Phase	Indication	Milestone
Pagibaximab (out-licensed to Biosynexus)	Phase II, IIa, IIb	Prevention of staphylococcal infection in neonates	Study completion targeted for 2010
ALT-801	Phase II, IIa, IIb	Metastatic p53+ malignancies	Completion study - 2Q09, Initiate Phase II efficacy study
ALT-836	Phase II, IIa, IIb	Acute Respiratory Distress Syndrome/Acute Lung Injury	Study initiation - 1Q09, Study completion - 2010
ALT-801 + Donor lymphocyte (NK cell) infusion	Phase I	Acute Myeloid Leukemia	Study initiation - 2Q09
ALT-802 / ALT-803 (TCR-Ig, TCR-IL15)	Preclinical	p53+ cancer	Complete preclinical efficacy studies, advance to clinical manufacture

SENIOR MANAGEMENT

Hing C. Wong, PhD, President & CEO • Peter Rhode, PhD, Vice President • Dean Taylor, PhD, Chief Business Officer • Jeffrey S. Weber, MD, PhD, Chief Medical Officer • Bee-Yau Huang, MS, Director • Shamay Tang, MS, Director • Pierre-Andre Chavaille, PhD, Director

FINANCING HISTORY

Round Date (Amount, US\$): February 2009 (2.0 million)

Investors: Sanderling Ventures (33%) • C. Boyden Gray & C. Boyden Gray Trust (14%) • Hing Wong & Bee-Yau Huang (10%) • The Audax Group (4%) • Chris & Ling Cheung (4%)

Anthera Pharmaceuticals, Inc.

Drug Development

Paul F. Truex President & CEO

25801 Industrial Blvd., Ste. B
Hayward, CA 94545
USA

www.anthera.com

1 (510) 856-5600

Incorporated: 2005

Ownership: Private

CORPORATE MISSION

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. Anthera's lead asset A-002 (varespladib) has successfully completed two Phase 2 studies and recently capped enrollment in the FRANCIS study. FRANCIS is examining the impact of varespladib when administered within 96 hours of an Acute Coronary Syndrome (ACS). FRANCIS will provide significant insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the trial.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
A-001	Phase II, IIa, IIb	Sickle Cell Disease
A-002	Phase II, IIa, IIb	Cardiovascular Disease
A-623	Phase II, IIa, IIb	Lupus

SENIOR MANAGEMENT

Paul F. Truex, President & CEO • James E. Pennington, MD, Chief Medical Officer • Colin Hislop, MD, Other

Arisaph Pharmaceuticals, LLC

Drug Development

Christopher Kiritsy

President & CEO

75 Kneeland Street, Ste. 401
Boston, MA 02111
USA

www.arisaph.com

1 (617) 292-3322

Incorporated: 1999

Ownership: Private

HIGHLIGHTS

Recent

The research collaboration between Abbott and Arisaph has yielded promising drug candidates and the collaboration has been extended through December 2009.

Arisaph and Fox Chase Cancer Center are collaborating to screen novel and innovative cancer compounds discovered, designed and synthesized by Arisaph.

CORPORATE MISSION

Arisaph Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing novel therapies for cancer, cardiovascular disease and diabetes. The company utilizes proprietary drug discovery platforms to develop differentiated medicines that are highly potent and act selectively on validated targets. Arisaph currently has seven active drug discovery programs in various stages of development.

PROPRIETARY TECHNOLOGY

Arisaph has successfully applied its proprietary specificity profiling and retro-inverso chiral chemistry technology platforms to synthesize several promising lead drug candidates, including a DPP IV inhibitor for Type II diabetes and reverse D-4F, an orally active apo A-I mimetic peptide for the treatment of atherosclerosis.

CORPORATE ALLIANCES

Abbott Laboratories; Fox Chase Cancer Center

SENIOR MANAGEMENT

Christopher Kiritsy, President & CEO • **William Bachovchin, PhD**, Chief Scientific Officer • **Claude Benedict, MD, PhD**, Vice President • **Robert Baldini**, Consultant

Ascent Therapeutics, Inc.

Biopharmaceuticals • Immunology • Oncology

Frederick (Rick) Jones, MD, MBA

President & CEO

67 Rogers Street
Cambridge, MA 02142
USA

www.ascentrx.com

1 (617) 715-1999

Incorporated: 2006

Employees: 14

Ownership: Private

HIGHLIGHTS

Recent

Company management, infrastructure and functions established since mid-2008.
25 patent applications filed in last six months.
First Pepducin Science Symposium held March 2009.

Upcoming

Selection of first pepducin preclinical development candidate mid-2009.

CORPORATE MISSION

Ascent Therapeutics creates high value for patients, physicians and investors by developing Pepducin-based drugs in a manner that earns the admiration and attention of the pharmaceutical industry.

PROPRIETARY TECHNOLOGY

Design and development of novel lipopeptides that modulate GPCR activity by interacting with the intracellular domains of the receptors.

CORPORATE ALLIANCES

Novartis

PRODUCTS

Name	Phase	Indication	Milestone
CXCR1/2 antagonist pepducin	Optimized Lead	Acute inflammation	Start preclinical development mid-year.
CXCR4 antagonist pepducin	Optimized Lead	Oncology	Chemosensitization study 2H09.
PAR1 antagonist pepducin	Research	Oncology	
Chemokine antagonist pepducin	Research	Acute and chronic inflammation	In vivo efficacy.

SENIOR MANAGEMENT

Frederick (Rick) Jones, MD, MBA, President & CEO • Stephen Hunt, PhD, Other • Tom McMurry, PhD, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): October 2007 (19.0 million)

Investors: Healthcare Ventures • TVM • Novartis Option Fund

Axial Biotech, Inc.

Diagnostics • Musculoskeletal

John M. Climaco Chief Executive Officer

2749 East Parley's Way
Salt Lake City, UT 84109
USA

www.axialbiotech.com

1 (801) 984-9100

Incorporated: 2003

Employees: 38

Ownership: Private

HIGHLIGHTS

Recent

Launch of ScoliScore. This new molecular based test is leading the way to individualized scoliosis treatment by providing patient-specific information that is used to help health care providers optimize treatment plans.

Identification of markers associated with early-onset, severe degenerative disc disease, and the filing of patents protecting these markers.

Upcoming

Publication of pivotal studies supporting the clinical use of ScoliScore - 2Q09.

Launch of tests to determine bracing efficacy for patients with moderate scoliosis at initial presentation, or for patients with an intermediate risk score on ScoliScore - early 2010.

Identification of initial marker panel for degenerative disc disease that is either prognostic of disease progression or predictive of treatment response.

CORPORATE MISSION

Delivering breakthrough diagnostics that improve and personalize the treatment of spine disorders.

PROPRIETARY TECHNOLOGY

ScoliScore™ is Axial Biotech's clinically validated, multi-gene test that provides a qualitative and quantitative assessment of the likelihood of spinal curve progression for patients who have been diagnosed with Adolescent Idiopathic Scoliosis (AIS). ScoliScore™ was launched in the United States in December, 2008 and will be distributed worldwide by DePuy Spine, a Johnson & Johnson company.

CORPORATE ALLIANCES

DePuy Spine

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
ScoliScore	On Market	scoliosis	
ScoliBrace	Diagnostics	scoliosis bracing efficacy	To be launched 2010.
degenerative disc disease prognostic	Research	degenerative disc disease	Complete marker panel - 2011.

SENIOR MANAGEMENT

John M. Climaco, Chief Executive Officer • **Ken Ward, MD**, Chief Scientific Officer • **Lesa Nelson**, Vice President • **Danielle Hayes**, Corporate Finance • **Eric Olson**, Vice President • **Joe Ross**, Vice President • **Rina Wolf**, Vice President • **Roberto Macina**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): January 2005 (4.1 million) • March 2007 (15.3 million)

Investors: **Johnson & Johnson Development Corp.** (23%) • **vSprin capital** (21%) • **Ohio Biotech Group** (7%) • **Medtronic** (4%)

Biopremiere Inc.

Biopharmaceuticals • Immunology • Hematology

Ramon Mohanlal Chief Executive Officer

120 Sylvan Avenue
Englewood Cliffs, NJ 07632
USA

www.biopremiere.com

1 (269) 352-5702

Incorporated: 2008

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

BioPremiere Inc. has acquired the rights for BP-001, a novel TNF-inhibitor and BP-002, a novel EPO-like protein.

CORPORATE MISSION

Our mission is to develop novel and premium biologics for serious diseases with a large market potential, in a risk-mitigated and expedited manner.

PROPRIETARY TECHNOLOGY

I. BP-001, a soluble TNF receptor has twice more binding sites for TNF, and superior efficacy in an animal model of RA compared to etanercept. II. BP-002, an EPO with an amino acid substitution, has a 100-fold higher affinity for the EPO receptor, and superior efficacy in an animal model of anemia compared to standard epoetin beta. These preclinical stage programs have blockbuster potential.

CORPORATE ALLIANCES

We are open to discuss alliances.

SENIOR MANAGEMENT

Ramon Mohanlal, Chief Executive Officer • **Hoon Chung**, President

BioRelix, Inc.

Infectious Disease • Biodefense

Brian R. Dixon, PhD *President & CEO*

5 Science Park
New Haven, CT 06511
USA

www.biorelix.com

1 (203) 785-9282

Incorporated: 2005

Ownership: Private

CORPORATE MISSION

BioRelix is discovering and developing new treatments for infectious diseases that target RiboSwitches – an innovative class of RNA drug targets found in pathogenic bacteria and fungi.

PROPRIETARY TECHNOLOGY

BioRelix owns a worldwide license to develop and market RiboSwitch targeted medicines. Discovered in the lab of Dr. Ronald Breaker, Riboswitches are short stretches of mRNAs that bind small molecules and control genes that are essential for the survival of many pathogenic microbes. Multiple classes of RiboSwitches have been identified and each has potential as a novel anti-infective drug target.

SENIOR MANAGEMENT

Brian R. Dixon, PhD, President & CEO

Boehringer Ingelheim GmbH

Cardiovascular Disease • Immunology • Oncology

Dr. Andreas Barner

Chairman

900 Ridgebury Road
Ridgefield CT, 06877
USA

www.boehringer-ingelheim.com

1 (203) 791-5950

Incorporated: 1885

Employees: 39,800

Ownership: Private

HIGHLIGHTS

Recent

Established a major collaboration with Vitae Pharmaceuticals to develop and commercialize 11beta-HSD1 inhibitors for diabetes and potentially other metabolic syndrome related indications.

Worldwide exclusive research and license agreement with Ablynx to discover and develop new therapies for Alzheimers disease.

Worldwide exclusive research and license collaboration with Biota to develop and commercialize Biotas novel nucleoside analogues designed to treat Hepatitis C Virus (HCV) infections and potentially other diseases.

Upcoming

Establishment of a new Production Alliance Network "PAN Biologics". Clients gain access to Boehringer Ingelheim's intellectual property rights for early stage product development and preferred access to large-scale manufacturing capacities.

CORPORATE MISSION

The Boehringer Ingelheim group is one of the worlds 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates and 39,800 employees. Growing faster than the market average for the eighth year in succession, Boehringer Ingelheim maintained its successful course as an independent and dynamically growing pharmaceutical company. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing innovative products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Our therapeutic areas are respiratory, cardiovascular, central nervous system, urology, virology, rheumatology, metabolism, immunology and oncology.

Boehringer Ingelheim is seeking partnerships, alliances and licensing opportunities with a primary focus in its therapeutic areas inflammation/immunology, cardiovascular, CNS, respiratory, virology, metabolism (obesity, diabetes), oncology and urology as well as in new approaches in vaccine development for Animal Health. We are also seeking new clients for late stage manufacturing of biopharmaceuticals in microorganisms or in cell culture.

PROPRIETARY TECHNOLOGY

Biopharmaceutical Development & Production: Boehringer Ingelheim is one of the leading contract manufacturing organizations (CMO) for development and production of biopharmaceuticals. We have a track record of 14 DNA-derived products that we have jointly with our partners brought to the market.

CORPORATE ALLIANCES

Our alliances range from early stage research to development and marketing or co-promotion collaborations. Complementing our in-house R&D efforts, these alliances are a vital component of our search for novel therapeutics which provide new treatment options for patients. Boehringer Ingelheim is seeking partnerships, alliances and licensing opportunities.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
SPIRIVA	On Market	Chronic obstructive pulmonary disease
MICARDIS	On Market	Hypertension
FLOMAX	On Market	Benign Prostatic Hyperplasia
COMBIVENT	On Market	Chronic obstructive pulmonary disease
SIFROL / MIRAPEX	On Market	Parkinson's disease and Restless Leg Syndrome
VIRAMUNE	On Market	HIV-1
ATROVENT	On Market	Chronic obstructive pulmonary disease
CATAPRES	On Market	All forms of high blood pressure
AGGRENOX	On Market	Stroke Prevention
ACTILYSE	On Market	Acute myocardial infarction, acute massive

Calistoga Pharmaceuticals, Inc.

Oncology • Pulmonary • Immunology

Carol Gallagher, PharmD

Chief Executive Officer

2101 Fourth Avenue
Seattle, WA 98121
USA

www.calistogapharma.com

1 (206) 728-4700

Incorporated: 2006

Employees: 22

Ownership: Private

HIGHLIGHTS

Recent

Presentation of preclinical data of CAL-101 demonstrating anti-tumor activity against range of hematologic malignancies (American Society of Hematology, Dec. 2008).

Initiated Normal Healthy Volunteer trial of second compound (December 2008).

Initiated Phase 1 Trial of CAL-101 in patients with hematologic malignancies (July 2008).

Upcoming

Cohort expansion in Phase 1 trial of CAL-101 in patients with hematologic malignancies in 2Q09.

Complete evaluation of second compound in normal healthy volunteers by mid-2009.

Initiate Phase 2 allergy/asthma trial in 2009.

CORPORATE MISSION

Calistoga Pharmaceuticals, Inc. is the leader in developing innovative medicines targeting selective isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.

PROPRIETARY TECHNOLOGY

Calistoga Pharmaceuticals' most advanced compound, CAL-101, is an oral, p110 delta selective PI3 kinase inhibitor that has been evaluated in normal healthy volunteers and is currently under clinical evaluation in patients with hematologic malignancies. A second compound, for treatment of asthma and other inflammatory diseases, is under evaluation in a clinical trial in normal healthy volunteers.

CORPORATE ALLIANCES

Calistoga Pharmaceuticals is a private, venture-backed company with top tier investors including Frazier Healthcare, Alta Partners, Three Arch, and Amgen Ventures. The company is led by a seasoned management team, with experience developing successful commercialized products.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
CAL-101	Phase I	Hematological Malignancies	Cohort expansion
Program 2	Phase I	Asthma/Allergy	Complete NHV trial

SENIOR MANAGEMENT

Carol Gallagher, PharmD, Chief Executive Officer • W. Michael Gallatin, PhD, President • Clifford J. Stocks, Chief Business Officer • Niell Giese, PhD, Chief Scientific Officer • Albert Yu, MD, Chief Medical Officer

Catena Pharmaceuticals, Inc.

Oncology

Ian J. Mehr

President

2530 Meridian Parkway, Suite 200
Durham, NC 27713
USA

www.catenapharma.com

1 (919) 806-4480

Incorporated: 2008

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

License completed with University of Virginia Patent Foundation in October 2008.
Funding received from the North Carolina Biotechnology Center in November 2008.

Upcoming

Strategic relationship with contract research organization in 1H09.

CORPORATE MISSION

While therapeutic advances have been made, cancer remains a scourge as the second leading cause of death in the United States, creating intense suffering and major economic costs on the healthcare system. Catena Pharmaceuticals's proprietary technology has demonstrated a unique ability to aggressively fight the growth of cancerous tumors in animal models. Catena's exciting drug platform attacks cancer through a validated drug target class and by a proven mechanism: blocking blood flow to tumors (angiogenesis) and starving them of oxygen. Catena seeks a Series A financing round of \$5 million to advance its lead anti-cancer drug candidate, VPC51299, towards human clinical trials.

PROPRIETARY TECHNOLOGY

VPC51299 antagonizes a subset of G-protein coupled receptors specific for lysophosphatidic acid (LPA). LPA is a serum lipid that promotes tumor growth, and the enzyme that manufactures LPA is a recognized cancer-related protein. VPC51299 is potent (low nM), orally available and non toxic, and delays the formation of cancerous tumors, and decreases the size of metastatic bone lesions.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
VCP51299	Preclinical	Oncology
VCP8 Series	Lead Series	Fibrosis

SENIOR MANAGEMENT

Ian J. Mehr, President • Kevin R. Lynch, PhD, Vice President • Timothy L. Macdonald, PhD, Vice President

Celtaxsys, Inc.

AutoImmune • Oncology • Drug Development

William P. (Bill) Reddick, MHA

President

311 Ferst Dr., ATDC Biosciences Ctr., #0390
Atlanta, GA 30332
USA

www.celtaxsys.com

1 (404) 920-0703

Incorporated: 2004

Employees: 8

Ownership: Private

HIGHLIGHTS

Recent

Purified chemorepellant proteins from ovarian cancer, renal cell carcinoma & colorectal cancer tissue.
Increased portfolio of validated small molecule chemorepellants.
Bridge funding of \$2 million

Upcoming

In vivo data on ISR- Adjuvant.
In vivo data on small molecule anti-inflammatory compound.
series C funding.

CORPORATE MISSION

Celtaxsys is principally involved in identifying the ligands, receptors and intracellular pathways involved in chemorepulsion. Chemorepulsion is the active movement away from a signal and is induced primarily by proteins which are not chemokines. We are focused on developing compounds which agonize or antagonize chemorepulsion. These compounds offer an alternative approach to diseases characterized by dysregulation of cell migration.

PROPRIETARY TECHNOLOGY

Celtaxsys is unique in its focus on the biological process of chemorepulsion. Proprietary technology, novel screening assays, and innovative researchers have allowed Celtaxsys to analyze a broad range of biologically active molecules (small molecules, peptides and proteins) that produce a chemorepulsive effect in vitro and in vivo.

CORPORATE ALLIANCES

Ovarian Cancer Institute, National Institutes of Health Filarial Research Lab-3, New York University, University of Georgia, Georgia Institute of Technology, McGill University, Centers for Disease Control, and undisclosed corporate partners.

PRODUCTS

Name	Phase	Indication	Milestone
CTX- 007	Preclinical	Injection site reaction- adjuvant	Animal data 3Q09.
CTX- 008	Preclinical	Ovarian Cancer	Animal data 2010

SENIOR MANAGEMENT

William P. (Bill) Reddick, MHA, President • Roland Gerritsen van der Hoop, MD, PhD, Chief Scientific Officer • Surendra J. Chavan, PhD, Managing Director • Ralph Grosswald, MPH, Director

FINANCING HISTORY

Investors: Master Capital Health Ventures (25%) • Marlin Fund Offshore, LTD (9%) • GLG North American Opportunity (Special Assets) Fund (7%) • Marlin Fund, LP (6%) • Evia Partners, LLC (6%)

Centrose, LLC

Drug Discovery • Infectious Disease • Oncology

James R. Prudent Chief Executive Officer

802 Deming Way
Madison, WI 53717
USA

www.centrose.info

1 (608) 836-0207

Incorporated: 2006

Employees: 8

Ownership: Private

HIGHLIGHTS

Recent

Centrose raised an additional \$2 million in seed capital in 2009 which increases the amount raised in total funding at over \$4 million.

Centrose won top ranking in the NCET National University Start-ups Competition. Centrose was among over 400 university start-ups that were considered for the award.

Centrose announced that two of its lead compounds were found to have potent anti-tumor efficacy in animal models. The human tumors were shown to undergo complete remission.

Upcoming

In March 2009, Centrose anticipates that the National Institute of Allergy and Infectious Disease will award Centrose a \$280,000 grant to commence work on its early stage anti-fungal program.

CORPORATE MISSION

Centrose is in business to discover novel drug leads using CarboConnect™. CarboConnect™ is a proprietary discovery platform that rapidly enhances drug and drug leads through the attachment of novel sugars. Through CarboConnect™, Centrose develops improved, proprietary versions of existing drugs and drug leads with large market potential and where significant unmet medical needs exist. To quickly build value, we out-license or partner leads early in the development cycle.

PROPRIETARY TECHNOLOGY

Centrose has exclusive rights to sugar enhanced drug leads and sugar enhancing technologies owned by the Wisconsin Alumni Research Foundation. This intellectual property estate includes both method and composition of matter directed at enhancing therapeutics.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
CEN07-W-102	Optimized Lead	Oncology - NSCLC
CEN08-243	Lead Series	Oncology - NSCLC
CEN08-244	Preclinical	Oncology

SENIOR MANAGEMENT

James R Prudent, Chief Executive Officer • **C. Richard Hutchinson**, Chief Scientific Officer

FINANCING HISTORY

Round Date (Amount, US\$): February 2009 (3.4 million)

Investors: **Founders** (54%) • **Angels** (37%) • **WARF** (9%)

Cequent Pharmaceuticals, Inc.

Biopharmaceuticals • Immunology • Oncology

Peter D. Parker President & CEO

One Kendall Square
Cambridge, MA 02139
USA

www.cequentpharma.com

1 (617) 995-7940

Incorporated: 2006

Employees: 28

Ownership: Private

HIGHLIGHTS

Recent

Pre-IND Meeting held with FDA (CBER) January 2009. Agreement reached on all issues

First ever primate proof of efficacy for an orally delivered RNAi drug presented at RNAi Keystone - Banff, Alberta, in February 2009

CORPORATE MISSION

Cequent Pharmaceuticals, Inc. is a pre-clinical biopharmaceutical company developing new therapeutics based on RNA interference (RNAi). Our strength is in our delivery technology which has been validated in primates and will enter the clinic in 2009. Cequent is focusing its efforts on the development of products to treat inflammatory bowel disease, familial polyposis as well as other colon cancer conditions, and HPV-derived cervical dysplasia.

PROPRIETARY TECHNOLOGY

Cequent has an exclusive license to a new technology, TransKingdom RNA-Interference (tkRNAi), which was invented at the GI Cancer Laboratory of Beth Israel Deaconess Medical Center, Harvard Medical School. Through our initial application of tkRNAi to gastrointestinal diseases, we are building an impressive body of evidence to support this breakthrough in RNAi delivery.

CORPORATE ALLIANCES

Novartis for one target in IBD arena. The Institut Pasteur for development of new bacterial carriers. Original technology developed with Beth Israel Deaconess Medical Center - a patient care, research and teaching affiliate of Harvard Medical School which ranks fourth in National Institutes of Health funding among independent hospitals nationwide.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
CEQ508	Preclinical	FAP	IND filing August 2009
CEQ600	Preclinical	IBD	Animal efficacy
CEQ601	Preclinical	IBD	Animal efficacy
CEQ602	Preclinical	IBD	Animal efficacy

SENIOR MANAGEMENT

Peter D. Parker, President & CEO • **Johannes Fruehauf**, Vice President • **Stephen Laroux**, Manager • **Alison Silva**, Manager • **Ted Hibben**, Chief Business Officer

FINANCING HISTORY

Round Date (Amount, US\$): November 2006 (15.0 million)

Investors: **Pappas Ventures** • **Ampersand Ventures** • **Novartis Option Fund** • **New England Partners** • **Yasuda Enterprise Development**

Critical Biologics Corporation

Infectious Disease • Renal • Diagnostics

Ashleigh Palmer Chief Executive Officer

110 Old Driftway Lane
Lebanon, NJ 08833
USA

www.criticalbiologics.com

1 (908) 439-9768

Incorporated: 2005

Ownership: Private

HIGHLIGHTS

Recent

Completion of Ph2a PK/safety study in Hong Kong
Successful development of prototype rapid pGSN ELISA
Development of high-yield commercial scale manufacturing process

Upcoming

Submission of US FDA IND
Ph2b human proof-of-concept in critical care patients at high risk of morbidity
Ph2a PK/safety study in end-stage renal disease patients on hemodialysis

CORPORATE MISSION

CBC is currently seeking investment for Ph2b clinical development of a breakthrough theranostic platform that promises to substantially reduce morbidity/mortality in critical care patients admitted to the ICU and ESRD patients on dialysis. CBC's platform detects life-threatening deficiencies in a vital protective protein called plasma gelsolin (pGSN) and restores levels to concentrations found circulating in the blood of healthy subjects. The role of pGSN is so important that evolution has conserved its molecular structure across a broad spectrum of animal species. When pGSN levels are abnormally low (hypogelsolinemia), the body's natural inflammatory response to harmful stimuli escalates out of control damaging the heart, lungs and other vital organs, usually resulting in death. The diagnosis of hypogelsolinemia is made by measuring a patient's pGSN blood levels using a proprietary CBC ELISA. Once hypogelsolinemia is detected, repletion of circulating pGSN reserves is accomplished using CBC's proprietary recombinant human pGSN. CBC has compiled a comprehensive database demonstrating strong correlation between hypogelsolinemia and increased complications and death in a variety of critical care conditions, including physical trauma, major surgery, bone marrow transplantation, burns, pneumonia and other severe infections and injuries. CBC has also demonstrated in a 200 subject study that ESRD patients dying within their first year of dialysis had severe hypogelsolinemia, whereas survivors did not. The study showed patients with severe hypogelsolinemia have a statistically significant and markedly elevated risk of cardiovascular and infection related death. This risk of death reaches 27-fold in hypogelsolinemic patients using a catheter for hemodialysis. These findings suggest CBC's proprietary diagnostic screening for hypogelsolinemia is the most powerful known predictor of death for ESRD patients within their first year of hemodialysis.

PROPRIETARY TECHNOLOGY

CBC's theranostic platform is a breakthrough approach that harnesses the body's innate mechanism for localizing inflammation at the site of injury or infection. The vital suppression of pathological systemic inflammatory response is managed by a protective protein called plasma gelsolin (pGSN) normally circulating at 250mg/L in the blood of healthy subjects.

CORPORATE ALLIANCES

CBC enjoys successful collaborations on multiple fronts and offers potential partners access to: a Ph2 theranostic protein replacement therapy; a diagnostic screening test for patients with CKD/ESRD and critical care patients at high risk of developing sepsis and death; a highly predictive screening tool to select high event rate populations to facilitate critical care drug development.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Solinex™	Phase II, IIa, IIb	Life-threatening systemic inflammatory response	Human POC
Solinex™	Phase II, IIa, IIb	End-stage renal disease	Human POC
SolinDx™	Diagnostics	Measurement of plasma gelsolin levels	FDA regulatory submission

SENIOR MANAGEMENT

Ashleigh Palmer, Chief Executive Officer • **Richard Straube, MD**, Chief Medical Officer

FINANCING HISTORY

Round Date (Amount, US\$): August 2006 (0.5 million) • January 2007 (8.5 million)

Investors: **Morningside** (57%) • **Founders** (30%) • **Management/Employees** (13%)

Cynvec LLC

Oncology • CNS

Frank Stonebanks

President & CEO

245 Park Ave, 39th Floor
New York, NY 10167
USA

www.cynvec.com

1 (212) 671-1708

Incorporated: 2004

Employees: 2

Ownership: Private

HIGHLIGHTS

Recent

Company hired first CEO, former J&J and IBM executive Frank Stonebanks.

Completed detailed business plan, financials, PPM, launched new company website, initiated meetings with investment community.

Completed technology transfer of key development components from NYU.

Completed first part of pre-clinical package.

Upcoming

Complete preclinical package.

Complete manufacturing scale up for GMP material.

File IND and initiate Phase I in ovarian cancer.

CORPORATE MISSION

Development stage, private, oncology focused, NYU spin out focused on apoptotic sindbis oncolytic viral vector targeting over expressed laminin receptor (LAMR) on the surface of many solid tumors. This receptor is also implicated in Alzheimer's, MS, Parkinson's and druggable targets have been identified through high throughput screening. Game changing platform technology that can be used therapeutically as a single agent or in combination with cytotoxics, mabs, etc. or as a new product to deliver payloads of choice (cytokines, genes) to tumor site. In vivo, quantitative, real time companion cancer diagnostic / biomarker application possible. Phase I to commence in 3Q09 in ovarian cancer with base vector, which has shown apoptotic capability. Scalable GMP production process developed. Very compelling single agent and combination therapy data. (tumor eradication and highly significant survival rates in very difficult pancreatic and ovarian models). Founded 2004, raised \$11 million through angels to date, seeking up to \$35 million to advance through end of Phase II. (\$10 million initial tranche to complete Phase I over next 18 months). Strong, experienced management / development team and SAB. Cynvec has engineered solutions to many of the obstacles that have held back other viral vector companies, and has points of differentiation that make it a superior approach. (RNA vector vs DNA so NOT gene therapy, only targets over expressed LAMR, payload carrying potential proven, diagnostic capacity)

PROPRIETARY TECHNOLOGY

Cynvec utilizes a genetically engineered, apoptotic, RNA, replication defective form of the wild type sindbis virus, that binds exclusively to over expressed laminin receptor on the surface of certain cancers.

CORPORATE ALLIANCES

NYU School of Medicine

PRODUCTS

Name	Phase	Indication	Milestone
CYN 101	Preclinical	ovarian cancer	IND
CYN 101	Preclinical	pancreatic cancer	IND
CYN 101	Preclinical	NSCLC	IND
CYN 101	Preclinical	breast cancer	IND
CYN 101	Preclinical	colorectal	IND

SENIOR MANAGEMENT

Frank Stonebanks, President & CEO • Richard Purcell, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): June 2004 (11.0 million)

Investors: Leonard Litwin (40%) • Steve Blumenthal (30%)

Cytox Limited

CNS • Diagnostics • Drug Discovery

Richard Hadden Chief Executive Officer

54 St John's Square
London EC1V 4JL
United Kingdom

www.cytoxgroup.com

44 (207) 2504210

Incorporated: 2004

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

2nd clinical study results:

- disease biomarker discriminates between AD/control patients with 80% specificity / 80% sensitivity;
- disease biomarker predicts cognitive decline in MCI patients ~10 years earlier than test-negative MCI patients.

Recent Pre-Series A fundraising closed (~\$900,000)

Upcoming

Research collaboration with major Pharma for patient screening and stratification services.

CORPORATE MISSION

Development of diagnostic and therapeutic products for use in drug development and clinical management of Alzheimer's disease/mild cognitive impairment, including clinical disease biomarkers; pharmacogenomic biomarkers; screens for drug discovery.

PROPRIETARY TECHNOLOGY

- 1) Cellular (lymphocyte) assay for prediction of progression to Alzheimer's disease-like dementia in MCI patients;
- 2) Genetic assays for AD/MCI patient sub-grouping, risk assessment and drug-selection;
- 3) Cellular assay for prediction of drug response in MCI/AD patients;
- 4) Drug screens for AD utility (NCE's; 2nd use drugs);
- 5) Therapeutic targets for AD

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Patient selection test for prediction of progression to dementia in MCI patients	Diagnostics	AD / MCI / dementia trials	Validated biomarker by FDA guidelines
Patient/drug response stratification biomarkers	Diagnostics	Alzheimer's disease /mild cognitive impairment	validated by FDA guidelines
drug screens for AD / MCI based on role of cell cycle in neurodegeneration	Other	Alzheimer's disease /mild cognitive impairment	Validated

SENIOR MANAGEMENT

Richard Hadden, Chief Executive Officer • **Jim Hawkins, PhD, MBA**, Chairman • **Zsuzsanna Nagy, MD DPhil**, Chief Scientific Officer • **Tim Tankosic, MD**, Chief Medical Officer • **Paul Davies**, Business Development

FINANCING HISTORY

Round Date (Amount, US\$): January 2009 (1.0 million)

Investors: **Midven Advantage Growth Fund (20%) • Angels (including Cambridge angels) (25%) • NESTA (5%) • Management (investment) (3%) • MASA Lifesciences Ventures (2%)**

DiaKine Therapeutics, Inc.

Drug Development • AutoImmune • Regenerative Medicine

Keith D. Igotz President & CEO

1414 Sachem Place
Charlottesville, VA 22901
USA

www.daikine.com

1 (434) 975-2001

Incorporated: 2004

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

Phase 2 NIH Funded study starts with DiaKine lead compound.
DiaKine's lead compound treats T2DM reducing inflammation.
DiaKine's lead compound and combination with neogenic peptide produced remission in 70% of the insulin dependent animals.

Upcoming

Completion of phase 1/2 trial May 09.
Start of phase 2 T1DM new onset trial.
Start of phase 2 established diabetes combination therapy trial.

CORPORATE MISSION

Develop therapies for large unmet medical needs in Type 1 and Type 2 diabetes.

PROPRIETARY TECHNOLOGY

Small molecule immune modulator.

CORPORATE ALLIANCES

CellGrow / MediaTech, NIH Islet Cell Consortium, Kinexum Metabolics, Inc., MicroIslet SBIR funded research.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
DT 002	Phase I	Diabetes	Sub Q delivery
DT 003 New Onset	Phase II, IIa, IIb	T1DM new onset	NDA approval
DT 004 Established diabetes	Preclinical	Established diabetes	NDA
DT 005	Preclinical	Diabetes	<i>In vitro</i> study

SENIOR MANAGEMENT

Keith D. Igotz, President & CEO • **Mary Ann Nadler**, Vice President • **Jerry L. Nadler, MD**, Chief Scientific Officer

FINANCING HISTORY

Round Date (Amount, US\$): February 2009

Investors: **Jerry and Mary Ann Nadler (36%) • Keith Igotz (10%) • Angels (54%)**

Dicerna Pharmaceuticals, Inc.

Oncology • Metabolic Disease • Infectious Disease

James Jenson, PhD President & CEO

480 Arsenal Street
Watertown, MA 02472
USA

www.dicerna.com

1 (617) 621-8097

Incorporated: 2006

Employees: 22

Ownership: Private

HIGHLIGHTS

Recent

Completed Series A financing with top tier VC groups in 2008 - Oxford, Skyline, and Abingworth. Obtained exclusive license to dicer-substrate RNAi technology for pharmaceutical uses, and sole right to sublicense dicer-substrates.

Demonstration of extraordinary in vitro (single digit picomolar) and in vivo (ablation) potency of dicer-substrate RNAi compounds targeting important oncogenes previously inaccessible to pharmaceutical intervention.

Upcoming

Pharma deal

IND enabling animal data

First patent claims to issue

CORPORATE MISSION

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for multiple indications based on its proprietary Dicer Substrate Technology, which triggers RNA interference, or RNAi, in a potent and specific manner.

PROPRIETARY TECHNOLOGY

Dicer Substrate Technology is a second generation RNAi technology that generates pharmaceutical compounds called dicer-substrates that have increased potency and duration of action compared to earlier approaches, because of the distinct way in which the compounds engage the RNAi pathway in mammalian cells.

CORPORATE ALLIANCES

Integrated DNA Technologies.

SENIOR MANAGEMENT

James Jenson, PhD, President & CEO • **Martin Williams**, Chief Business Officer • **Roberto Gueriolini, MD**, Vice President • **Bob Brown, PhD**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): July 2008 (21.4 million)

EnzymeRx LLC

Musculoskeletal • Drug Development • Drug Delivery

Tony Fiorino, MD, PhD

President & CEO

17 Arcadian Avenue
Paramus, NJ 07652
USA

www.enzymerx.com

1 (201) 843-4424

Incorporated: 2008

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Recently added John Zhang, MD, PhD as Vice President, Preclinical Research and Development, who most recently was Director, Preclinical Pharmacology and Toxicology at Pharmacoepia.

Recently added Elizaeth John, PhD as VP, Manufacturing. Elizabeth most recently served as Head of R&D at Centegen, a biotechnology start-up.

Held separate meetings with the FDA with respect to our existing gout IND and our pending tumor lysis syndrome IND and came to agreement with the Agency on issues relating to clinical trial design, required toxicology studies, and manufacturing.

Upcoming

We expect to complete the studies needed to allow the amending of our gout IND and to file our tumor lysis syndrome IND in the 2Q09, followed by the filing of these documents.

We expect to launch new clinical studies in the 2H09.

We expect to announce an important agreement with a new manufacturer in the 1H09.

CORPORATE MISSION

EnzymeRx is a private biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and tumor lysis syndrome. Despite a modest infrastructure, we are committed to a robust and detail-oriented approach to all aspects of drug development - CMC, preclinical, clinical and regulatory. With this approach, we can build a complete, thoughtful and high quality data package around uricase-PEG 20. This focus is critical as we intend to seek a partner for uricase-PEG 20 at the conclusion of phase II or phase III, and we believe this approach will enhance the attractiveness and value of our assets.

PROPRIETARY TECHNOLOGY

Uricase-PEG 20

PRODUCTS

Name	Phase	Indication
Uricase-PEG 20	Phase I	Gout, Refractory
Uricase-PEG 20	Preclinical	Tumor Lysis Syndrome

SENIOR MANAGEMENT

Tony Fiorino, MD, PhD, President & CEO • **John Bomalaski, MD**, Chief Medical Officer • **Elizabeth John, PhD**, Vice President • **John Zhang, MD, PhD**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): February 2009 (14.0 million)

Investors: **Pequot Capital (70%) • Polaris Pharmaceuticals (30%)**

FluGen, Inc.

Vaccines • Infectious Disease

Paul V. Radspinner

President & CEO

545 Science Drive
Madison, WI 53711
USA

www.flugen.com

1 (608) 658-6095

Incorporated: 2007

Employees: 7

Ownership: Private

CORPORATE MISSION

FluGen's mission is to turn promising advances in the development, production and delivery of influenza vaccines and related infectious disease products into solutions for patients and their families that improve health and well being. FluGen will achieve its mission by advancing a product pipeline that addresses significant unmet customer needs and that takes full advantage of its unique technologies.

SENIOR MANAGEMENT

Paul V. Radspinner, President & CEO • **Pamuk Bilseel, PhD**, Vice President

FORMA Therapeutics, Inc.

Oncology • Drug Discovery • Chemistry

Steven Tregay, PhD

President & CEO

790 Memorial Drive
Cambridge, MA 02139
USA

www.formatherapeutics.com

1 (617) 679-1970

Incorporated: 2007

Employees: 40

Ownership: Private

HIGHLIGHTS

Recent

January 12, 2009: FORMA Therapeutics, Inc. announced it has entered into a license and option agreement through the Novartis Option Fund to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology.

January 26, 2009: FORMA Therapeutics, Inc. announced it has signed a collaboration agreement with Cubist Pharmaceuticals, Inc. to discover novel antibacterial compounds for development by Cubist.

CORPORATE MISSION

FORMA Therapeutics, Inc. is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.

PROPRIETARY TECHNOLOGY

FORMA is uniquely positioned through its unprecedented combination of technological capabilities in structure guided drug discovery, diversity oriented synthesis and proprietary cell-based screening to access novel target space and to develop a new generation of breakthrough drugs.

CORPORATE ALLIANCES

FORMA has announced alliances with Novartis Pharmaceuticals valued up to \$200 million and a collaboration with Cubist Pharmaceuticals valued up to \$60 million.

SENIOR MANAGEMENT

Steven Tregay, PhD, President & CEO • **Nikolai Kley, PhD**, Vice President • **James Kyranos, PhD**, Vice President

FINANCING HISTORY

Investors: **Novartis Venture Funds • Bio*One Capital of Singapore**

GliaMed, Inc.

Skin/Dermatological • Cardiovascular Disease • Musculoskeletal

Andrew C. G. Uprichard, MD, PhD

President & CEO

495 Old Connecticut Path
Framingham, MA 01701
USA

www.gliamed.com

1 (508) 626-0077

Incorporated: 2001

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Initiation of development of topical formulation of lead compound.

Hiring of a pharma-experienced CEO and establishment of corporate headquarters in Boston.

CORPORATE MISSION

GliaMed is a development-stage biopharmaceutical company dedicated to making Regenerative Medicine a reality through the discovery and development of drugs to accelerate the human body's innate ability to regenerate. Founded in 2001 the company is focused on the development of small molecule therapeutics that induce autologous stem cells in vivo at the site of trauma or injury. The company's lead product candidate has demonstrated activity in in vitro and in vivo models of wound healing, cartilage and bone regeneration and regeneration of myocardium following induced MI. This product candidate has been given by oral, parenteral and topical routes.

PROPRIETARY TECHNOLOGY

Regenerative Immunophilin Ligands (RILs), small molecules based on FK506 that do not exhibit immunosuppressant activity.

CORPORATE ALLIANCES

None. Part of the strategy in developing GM1485

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
GM1485 - Topical	Preclinical	Wound healing
GM1485 - Parenteral	Preclinical	Cardiac remodeling following MI
GM1485 - Parenteral	Other	Cartilage and bone repair following acute trauma
GM1485 - Oral	Other	follow-on indications

SENIOR MANAGEMENT

Andrew C.G. Uprichard, MD, PhD, President & CEO • David E. Weinstein, MD, PhD, Chief Scientific Officer

Great Basin Scientific, Inc.

Diagnostics • Infectious Disease • Reproductive

Ryan Ashton Chief Executive Officer

405 South Main Street Suite 810
Salt Lake City, UT 84111
USA

www.gbscience.com

1 (801) 596-2896

Incorporated: 2003

Employees: 16

Ownership: Private

CORPORATE MISSION

Great Basin Scientific is a rapid molecular diagnostics company. We have developed a chip-based, non-PCR point of care test platform. Great Basin Scientific is pre-revenue, beyond discovery risk, with first approved products in about 12 months. Company operations are in Longmont, Colorado with a corporate office in Salt Lake City. The management team has a successful track record in commercializing low-cost, chip-based diagnostic tests.

PROPRIETARY TECHNOLOGY

The Great Basin system entails an integrated single-use cartridge containing all reagents. The cartridge is processed by a benchtop analyzer that executes the molecular assay, interprets the results and provides electronic output to the clinician in less than one hour at significantly lower-cost than currently available automated real-time PCR solutions.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
MRSA surveillance	Diagnostics	MRSA from positive blood culture	510(k) submission in 3Q09.
MRSA surveillance	Diagnostics	MRSA diagnosis from positive blood culture	510(k) submission in 3Q09.
MRSA screening	Diagnostics	MRSA diagnosis from nasal swab	510(k) submission early 2010

SENIOR MANAGEMENT

Ryan Ashton, Chief Executive Officer • **Jeff Selander**, Chief Financial Officer • **Rob Jenison**, Chief Technology Officer • **Larry Rea**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): January 2005 (3.5 million) • April 2008 (3.9 million)

Investors: **Calico Consortium** (14%) • **David Spafford** (12%) • **Lynn Briggs** (11%) • **Ryan Ashton** (5%) • **Yale University** (5%)

Helixis, Inc.

Diagnostics • Industrial Biotech • Pharmacogenetics

Alex Dickinson, PhD

President & CEO

5421 Avenida Encinas
Carlsbad, CA 92008
USA

www.helixis.com

1 (760) 470-4862

Incorporated: 2007

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

PIXO prototype running real time PCR with excellent performance. Results presented at recent conference by an independent medical diagnostics researcher.

Key subcontractor in production of core thermal unit of the product; all subcontractors on track for September launch.

Demonstrated complete protocol required for 20 minutes sample-to-answer diagnostic real time PCR product.

Upcoming

Pre-production units April 2009.

Pilot production units June 2009.

Full production Sept. 2009.

CORPORATE MISSION

Helixis is commercializing a proprietary, high-performance and low-cost real time PCR technology developed in a unique cross-disciplinary collaboration between Caltech professors David Baltimore (Caltech president-emeritus & Nobel Laureate in Medicine) and Axel Scherer (renown nanotechnologist).

PROPRIETARY TECHNOLOGY

High speed/high performance heating and cooling techniques for real time PCR; - Fast, efficient, and low cost sample preparation techniques

CORPORATE ALLIANCES

Confidential

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
PIXO Real Time PCR	Other	Life science research	Shipping Sept. 2009.
PIXO life science reagents	Other	Specialized reagents kits for researchers	Shipping 1Q10.
CABO Sample-to-answer diagnostic instrument	Diagnostics	For small lab and POC	Breadboard running assays 4Q09.

SENIOR MANAGEMENT

Alex Dickinson, PhD, President & CEO • **Adrian Fawcett**, Vice President • **Judy Macemon**, Vice President • **Xing Yang, PhD**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): August 2007 (10.0 million)

Investors: **Domain Associates (25%) • Advanced Technology Ventures (18%) • Okapi Ventures (7%)**

HemaQuest Pharmaceuticals, Inc.

Biopharmaceuticals • Hematology • Drug Development

Ron Berenson, MD Chief Executive Officer

1229 Madison Street
Seattle, WA 98104
USA

www.hemaquest.com

1 (206) 682-1233

Incorporated: 2007

Employees: 11

Ownership: Private

HIGHLIGHTS

Recent

Completion of Phase 1 clinical trials for HQK-1001.
Orphan Drug Designation in Europe and US for HQK-1001.
FDA acceptance of IND to start clinical trials in thalassemia and sickle-cell anemia for HQK-1001.

Upcoming

Start clinical trials in thalassemia and sickle-cell anemia for HQK-1001.
Initiation of clinical trial in viral-related malignancies for HQK-1004.
Filing IND for HQK-1003.

CORPORATE MISSION

Development of pharmaceuticals to treat benign and malignant hematological disorders.

PROPRIETARY TECHNOLOGY

- 1) short-chain fatty acid derivatives that modulate gene expression;
- 2) combination of viral-inducing agent and anti-viral agent to treat viral-related diseases including cancer.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
HQK-1001	Phase II, IIa, IIb	sickle-cell anemia, thalassemia	proof of concept
HQK-1002	Research	neutropenia	proof of concept
HQK-1003	Target Validated	sickle-cell anemia, thalassemia	IND
HQK-1004	Phase I	viral-related cancer	proof of concept

SENIOR MANAGEMENT

Ron Berenson, MD, Chief Executive Officer • **Susan Perrine, MD**, Chief Scientific Officer • **Patrick Bobbitt**, Vice President • **Elsa Johnson**, Director

FINANCING HISTORY

Round Date (Amount, US\$): October 2007 (20.0 million)

ImmunoVaccine Technologies Inc.

Vaccines • Oncology • Infectious Disease

Randal Chase President & CEO

1819 Granville St.
Halifax, Nova Scotia B3J 3R1
Canada

www.immunovaccine.com
1 (902) 492-1819

Incorporated: 2000
Employees: 17
Ownership: Private

HIGHLIGHTS

Recent

DepoVax™ Shows Positive Results for Cancer and Infectious Diseases in therapeutic cancer and several infectious disease vaccine models.

ImmunoVaccine Technologies Broadens Its Patent Protection to Japan.

ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria.

Upcoming

IVT files IND for Therapeutic Cancer Vaccine for Prostate, Breast, and Ovarian Cancer.

IVT closes funding round.

CORPORATE MISSION

ImmunoVaccine Technologies Inc. (IVT) is a development stage vaccine biotechnology company committed to the commercialization of best-on-class single-dose vaccine candidates against deadly diseases.

PROPRIETARY TECHNOLOGY

The DepoVax™ platform represents a true breakthrough. A long-lasting 'depot effect' is created at the site of injection that slowly release antigen and elicited a potent humoral and/or cellular immunity with just a single dose. destruction by cytotoxic T lymphocytes.

CORPORATE ALLIANCES

Pfizer Animal Health: Rights to two veterinary vaccines and an option for a third; Dalhousie University; NIAID to use HIV and Malaria antigens in DepoVax.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
DPX-0907	Preclinical	Breast, Prostate and Ovarian Cancer	IND in early 2009.
Single Dose Pandemic Flu Vaccine	Preclinical	Pandemic Flu	Ferret Challenge Studies in early 2009.
Hepatitis B single-dose Vaccine	Preclinical	Hepatitis B	
DepoVax	Research	Platform for Vaccine formulation and Delivery	

SENIOR MANAGEMENT

Randal Chase, President & CEO • **Brian Lowe**, Vice President • **Ron Smith**, Vice President • **Marc Mansour**, Vice President • **Jeff Skinner**, Business Development

BOARD OF DIRECTORS

Randal Chase, President, IVT • **Brian Lowe**, Vice President, IVT • **Ron Smith**, Vice President, IVT

SCIENTIFIC ADVISORY BOARD

Dr. W. Martin Kast, Academic

Japan Tobacco, Inc.

Metabolic Disease • Infectious Disease • Immunology

1-1 Murasaki-cho,
Takatsuki 569-1125
Japan

www.jti.co.jp/JTI_E/outline/pharma2.html

81 (72) 681-9727

Incorporated: 1898
Employees: 2,300
Ownership: Public
Tokyo Stock Exchange: 2914

HIGHLIGHTS

Recent

JT has recently completed an outlicensing agreement with Roche on a lipid regulating drug and with Gilead on anti-HIV drug. They have several compounds currently in various stages of clinical and preclinical development.

CORPORATE MISSION

The pharmaceutical division of Japan Tobacco is a fully-integrated pharmaceutical entity dedicated to the discovery, development and marketing of novel human therapeutics. Their focus is on the identification of small molecule, orally available drugs to treat a variety of diseases, including metabolic diseases (diabetes, obesity, lipid regulation, osteoporosis), autoimmune/inflammatory diseases (IBD, asthma, allergy, etc.) and certain viral diseases (hepatitis C and HIV only).

JT seeks partnering opportunities to facilitate new drug discovery and development, such as new drug targets, HTS assays, cell lines, animal models, predictors of ADME and toxicology, compound libraries, lead compounds, etc. Early stage projects are welcome.

The types of relationships formed range from licensing to active R&D collaborations to contract arrangements. Flexibility for excellent science is the hallmark of JT's partnering philosophy.

PROPRIETARY TECHNOLOGY

JT has all of the capabilities and technologies necessary for new drug discovery and development. JT's preclinical R&D work is performed at their Central Pharmaceutical Research Institute located near Osaka. They have a molecular biology research laboratory in Yokohama and a toxicology in Hadano, Japan. They have a North American clinical development group in Princeton, NJ at Akros Pharma.

CORPORATE ALLIANCES

JT has successfully established a number of strategic alliances with several bio-pharmaceutical companies outside of Japan. Examples include: Abgenix - Human Monoclonal Antibody (XenoMouse™), Agouron/Pfizer (co-development of Viracept™, HIV protease inhibitor), Keryx bioPharmaceuticals (Zerenex™, phosphate binder), MedImmune (JTA-009, anti-ICOS Monoclonal Antibody), Glaxo (MEK Inhibitor)

Kinex Pharmaceuticals, LLC

Oncology • AutoImmune • Drug Discovery

Allen Barnett Chief Executive Officer

701 Ellicott St.
Buffalo, NY 14203
USA

www.kinexpharma.com

1 (716) 881-8969

Incorporated: 2004

Employees: 10

Ownership: Private

HIGHLIGHTS

Recent

Completion of Phase I clinical studies with KX2-391.
Selection of development candidate designated as KX-02 for the treatment of brain tumors.

Upcoming

Selection of IND candidate from one of the immuno-inflammatory targets currently being pursued.

CORPORATE MISSION

To fully exploit the Mimetica technology platform for the discovery and development of selective, non-ATP-competitive inhibitors of src and other signalling pathways for the treatment of various tumors and immuno-inflammatory disorders. Kinex will build shareholder value by progressing its candidates through clinical proof-of-concept and then partnering with pharma companies.

PROPRIETARY TECHNOLOGY

Mimetica technology for the design and synthesis of non-ATP competitive inhibitors of kinases and phosphatases.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
KX2-391	Phase II, IIa, IIb	Different types of cancer	Start of Phase II
KX-02	Other	Brain tumors	Initial safety studies for the IND and Phase I
KX-03	Optimized Lead	Autoimmune diseases	Selection of one compound for IND development and clinical trials

SENIOR MANAGEMENT

Allen Barnett, Chief Executive Officer • **David Hangauer**, Vice President • **Lyn Dyster**, Vice President

FINANCING HISTORY

Investors: **Allen Barnett** (16%) • **David Hangauer** (13%) • **Johnson Lau** (12%) • **Lyn Dyster** (4%)

Kyorin USA, Inc.

Metabolic Disease • Infectious Disease • AutoImmune

Kiyoo Uehara

President

500 Frank West Burr Boulevard
Teaneck, NJ 07666
USA

www.kyorinusa.com/en/

1 (201) 287-0110

Incorporated: 2001

Ownership: Private

CORPORATE MISSION

Kyorin USA was established in 2001 as a US subsidiary of Kyorin Pharmaceutical Co., Ltd. in Japan. Our company looks for licensing/business opportunities for Japanese market, particularly in the following therapeutic areas: respiratory, urology, ENT (ear, nose, throat) and IBD (Crohn's disease and ulcerative colitis). Kyorin Pharmaceutical is a fully-integrated pharmaceutical company with annual sales of over \$800 million in Japan and a track record of successful partnership with many companies.

CORPORATE ALLIANCES

Co-marketing of montelukast in Japan (with Merck), US marketing of Zymar (by Allergan), etc.

SENIOR MANAGEMENT

Kiyoo Uehara, President

LineaGen, Inc.

Diagnostics • CNS • Neurology

Michael S. Paul, PhD

President & CEO

423 Wakara Way, Suite 200
Salt Lake City, UT 84108
USA

www.lineagen.com

1 (801) 931-6200

Incorporated: 2006

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Closed \$5.85 million Series A Financing in October 2007 with Sanderling Ventures, vSpring Capital, and Mesa Verde Venture Partners.

Completed genetic analysis in Autism and Multiple Sclerosis with University of Utah, Vanderbilt University, and Affymetrix.

Secured a \$2 million venture debt facility.

Upcoming

Publication of a peer-reviewed journal article highlighting the results of genetic analysis, sequence capture, and sequencing of DNA samples from large, multiplex Autism pedigrees

Publication of a peer-reviewed journal article highlighting the results of genetic analysis performed on DNA samples from large, multiplex pedigrees and a large case/control cohort of Multiple Sclerosis

Closing of a Series B preferred equity financing

CORPORATE MISSION

LineaGen, Inc. is a Salt Lake City-based specialty diagnostics company that provides innovative tests and services for the earlier and more informative diagnoses of Autism and Multiple Sclerosis. LineaGen will provide diagnostic testing services through a CLIA-certified laboratory, including proprietary tests discovered and developed as a result of LineaGen's core genetic research programs as well as current standard-of-care tests. Integrated with LineaGen's laboratory testing will be value-add services including comprehensive, personalized interpretation of test results, secure electronic communication/web portal for reporting and client queries, clinical and genetic counseling for patients, their families, and their physicians, and consultation/advocacy for Third-Party Payor reimbursement.

This innovative approach of offering an integrated suite of laboratory tests and ancillary services targeting one disease ("specialty diagnostics") will dramatically enhance the patient's and physician's ability to manage complex diseases such as Autism and MS. In adopting this unique business model, LineaGen's mission is to become the leader in Autism and MS specialty diagnostic testing services. We believe that our comprehensive diagnostic services will dramatically improve the accuracy and cost of diagnosis, will lead to earlier and more personalized disease intervention and management, and will improve the quality of life for patients and their families.

PROPRIETARY TECHNOLOGY

LineaGen has broad access to genetic resources that are uniquely available in Utah. These resources include the Utah Population Database. Utah's genetic discovery resources have enabled more disease gene discoveries than in any other single location world-wide. Many of these genes are now successfully marketed as molecular diagnostics by companies such as Myriad Genetics and Clinical Data.

CORPORATE ALLIANCES

University of Utah, Vanderbilt University, and Battelle Memorial Institute.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Autism Diagnostic Test	Diagnostics	Autism	Replication Underway
Multiple Sclerosis Diagnostic Test	Diagnostics	Multiple Sclerosis	Replication Underway
COPD Discovery	Research	Chronic Obstructive Pulmonary Disease	Replication Complete

SENIOR MANAGEMENT

Michael S. Paul, PhD, President & CEO • **Mark F. Leppert, PhD**, Other • **Alex S. Lindell**, Business Development • **Tricia Kritzberg**, Corporate Finance • **Andreas Peiffer, MD, PhD**, Other

FINANCING HISTORY

Round Date (Amount, US\$): October 2007 (5.85 million)

Investors: **Sanderling Ventures • vSpring Capital • Mesa Verde Venture Partners**

Merck & Co., Inc.

Mr. Richard T. Clark Chief Executive Officer

One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889
USA

www.merck.com

1 (423) 4350

Incorporated: 1891
Employees: 59800
Ownership: Public
NYSE: MR

CORPORATE MISSION

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life.

At Merck, our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2008 were \$23.9 billion and Merck continues to invest heavily in research and development.

Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, elevated cholesterol levels, diabetes, cancer, osteoporosis, asthma, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, infectious diseases (antibiotic, antifungal, and antiviral agents), and vaccines (to prevent childhood diseases, human papilloma virus, rotavirus, shingles, and hepatitis A and hepatitis B).

To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Tel: 908-423-4350; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review. For further information, please visit our Web site at <http://www.merck.com/licensing/>.

CORPORATE ALLIANCES

At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. Approximately 65% of our 2008 sales were from alliance products and patents, including some of our biggest growth drivers.

SENIOR MANAGEMENT

Mr. Richard T. Clark, Chief Executive Officer • **Willie A. Deese**, President • **Kenneth C. Frazier**, President • **Mirian Graddick-Weir**, Vice President • **Peter N. Kellogg**, Chief Financial Officer • **Peter S. Kim, PhD**, President • **Bruce N. Kuhlik**, Vice President • **J. Chris Scalet**, Vice President

Mirna Therapeutics Inc

Drug Discovery • Oncology • Drug Delivery

Matt Winkler Chief Executive Officer

2150 Woodward Street
Austin, TX 78744
USA

www.mirnarx.com

1 (512) 901-0900

Incorporated: 2007

Ownership: Private

HIGHLIGHTS

Recent

Six therapeutic candidates for multiple different tumor types.

Access to two effective delivery technologies.

CORPORATE MISSION

Mirna Therapeutics, Inc., a wholly-owned subsidiary of Asuragen, Inc., to advance the pioneering work in miRNA therapeutics initiated by scientists at Asuragen. In keeping with the tradition of its parent company, Mirna therapeutics employs world class researchers with experience in oncology, molecular biology, biotechnology and medicine. Mirna's mission is the development of therapies that address various human diseases with significant unmet medical needs. Mirna's most advanced programs are directed toward oncology and include therapies for prostate cancer, non-small cell lung cancer and acute myeloid leukemia. Mirna Therapeutics has exclusive access to Asuragen's therapeutically-relevant intellectual property, and will exploit Asuragen's long-standing collaborations with top universities and biopharmaceutical companies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

PROPRIETARY TECHNOLOGY

microRNA mimetics, microRNA delivery technology. Mirna is a platform company featuring miRNA drug candidates with therapeutic activity against multiple cancers and a technology platform that enables the rapid identification of miRNA therapeutic candidates for many diseases.

CORPORATE ALLIANCES

MD Anderson, Yale University, University of California - San Francisco, NCCRI-Japan

PRODUCTS

Name	Phase	Indication
let-7	Preclinical	Lung cancer
miR-Rx04	Preclinical	Metstatic prostate cancer

SENIOR MANAGEMENT

Matt Winkler, Chief Executive Officer • **Rollie Carlson**, President • **Lynne Hohlfeld**, Chief Financial Officer • **Ana Ward**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): April 2008 (3.0 million)

Mithridion, Inc.

CNS • Drug Development • Drug Discovery

Trevor M. Twose, PhD

Chief Executive Officer

505 Science Drive
Madison, WI 53711
USA

www.mithridion.com

1 (608) 443-2430

Incorporated: 2004

Employees: 10

Ownership: Private

HIGHLIGHTS

Recent

Acquired Cognitive Pharmaceuticals in June 2008; bringing muscarinic agonist product platform and near-IND drug candidate. Built powerful drug lead-optimization and efficient semi-virtual drug development team with strong experienced management.

Raised \$2.9 million in venture funding in January 2009, which together with cash reserves will fund completion of Phase I and associated non-clinical work on MCD-386, and development of additional pipeline drug candidates.

Added three company patent applications to IP portfolio.

Upcoming

Complete Phase I clinical trials of MCD-386 and start non-clinical work for Phase II in Alzheimer's disease; start Phase II trials.

Prepare MCD-386 for clinical evaluation for cognitive deficit in schizophrenia.

Identify back-up/follow on drug candidate for AD and drug candidate for schizophrenia.

CORPORATE MISSION

Mithridion discovers and develops drugs for serious central nervous system (CNS) disorders, with an initial focus on Alzheimer's disease and schizophrenia. Our goal is to add great value in preclinical and clinical development, partnering drugs with major pharmaceutical or biotechnology companies at latest after demonstrating proof-of-concept in Phase II, realizing high returns for investors through a trade sale or IPO.

PROPRIETARY TECHNOLOGY

Mithridion has designed and developed selective agonists for M1 and M4 sub-types of muscarinic receptors to improve memory and cognition in AD patients, and potentially reduce neuron death ("disease-modifying"), without the side effects caused by activating M2 or M3 receptors. Selective M1, M4 and mixed M1/M4 agonists should potentially improving cognition and be anti-psychotic in schizophrenia.

CORPORATE ALLIANCES

None currently

PRODUCTS

<u>Name</u>	<u>Phase</u>	<u>Indication</u>	<u>Milestone</u>
MCD-386	Phase I	Alzheimer's disease/cognition and disease-modifying	Start Phase II
MCD-386 (2)	Preclinical	Schizophrenia/cognitive deficit	Start Phase I
MCD-386 back-up/follow-on	Lead Series	Alzheimer's disease/cognition and disease-modifying	Drug candidate
Schizophrenia	Lead Series	Schizophrenia/cognitive deficit and anti-psychotic	Drug candidate

SENIOR MANAGEMENT

Trevor M. Twose, PhD, Chief Executive Officer • **Bruce G. McCarthy, MD, MBA**, Chief Medical Officer • **Richard Copp, PhD**, Other • **Patti A. Twose**, Other • **Jennifer Nordloff, CPA**, Other

FINANCING HISTORY

Round Date (Amount, US\$): April 2007 (2.19 million) • January 2009 (5.23 million)

Investors: **Venture Investors (36%)** • **State of Wisconsin Investment Board (11%)** • **Rocket Venture Fund (5%)** • **Wisconsin Investment Partners (4%)** • **Rosetta Partners (3%)**

Nanotherapeutics, Inc.

Biopharmaceuticals • Drug Delivery • Biodefense

James Talton, PhD Chief Executive Officer

13859 Progress Blvd.
Alachua, FL 32615
USA

www.nanotherapeutics.com

1 (386) 462-9663

Incorporated: 1999

Employees: 21

Ownership: Private

CORPORATE MISSION

Nanotherapeutics, Inc. is an emerging specialty pharmaceutical company with expertise in the early stage development of pharmaceuticals. The company employs several platform technologies to manipulate and enhance the properties of drugs. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

CORPORATE ALLIANCES

Orthofix, Noramco

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Origen DBM with Bioactive Glass	On Market	General Orthopedic	
NanoFUSE	Other	General Orthopedic	Filed with FDA
NanoDOX 1% Doxycycline Monohydrate Hydrogel	Phase II, IIa, IIb	Wound Healing	
NanoBUP Buprenorphine/Naloxone Capsule	IND Filed	Opiate Addiction	

SENIOR MANAGEMENT

James Talton, PhD, Chief Executive Officer • **Dennis Tomisaka, MSE, MBA: Operations**, Vice President • **Dennis Kristof, CMA, MBA: Controller**, Vice President • **Jim Kirk, PhD: R&D**, Vice President • **Barb Eppler, PhD: Preclinical and QA**, Vice President • **John Abernethy, MD: Medical Director**, Other

NeurAxon, Inc.

CNS

Lawrence Bloch, MD, JD Chief Executive Officer

480 University Ave
Suite 900
Toronto, M5G 1V2
Canada

www.neuraxon.com
1 (416) 673-6697

Incorporated: 2004
Employees: 15
Ownership: Private

HIGHLIGHTS

Recent

Dual action first-in-class nNOS inhibitor and 5HT agonist for migraine has proven to be safe and well tolerated in doses up to 800mg in 237 subjects and patients to date. Three migraine efficacy trials will commence in 2Q09.

Identification and characterization of nNOS inhibitors with selectivity over eNOS and potential in Neuropathic Pain.

Identification and characterization of nNOS/iNOS inhibitors with selectivity over eNOS and potential in inflammatory pain states such as Rheumatoid Arthritis.

Upcoming

NXN-188 Phase 2 data in Migraine in 1Q10.

nNOS inhibitor Phase 1 data in Neuropathic Pain in 1Q10.

nNOS/iNOS inhibitor Phase 1 data in Rheumatoid Arthritis in 1Q10.

CORPORATE MISSION

NeurAxon is a company dedicated to developing first-in-class therapies for the treatment of central nervous system (CNS) disorders. Our initial focus is on chronic and recurring pain states which are currently large markets of unmet need and with few innovative or effective products.

NeurAxon will introduce novel neuronal NOS inhibitors into the market, NOS inhibition being a clinically validated target in pain but with as yet no products available for the clinical arena. NeurAxon aims to be the first company to exploit this technology effectively to produce drug therapies with greater efficacy and thereby expand the treated patient group.

PROPRIETARY TECHNOLOGY

NeurAxon has proprietary knowledge in the regulation of nitric oxide Synthase (NOS) family of enzymes. Using in-house molecular design NeurAxon is able to create selective inhibitors of NOS isoforms which are active in multiple functional models including chronic pain models and a novel migraine pain model.

CORPORATE ALLIANCES

University of Arizona: Animal models of neuropathic pain and migraine.

McMaster University Institute of Pain Research and Care: Central and Neuropathic Pain.

PRODUCTS

<u>Name</u>	<u>Phase</u>	<u>Indication</u>	<u>Milestone</u>
nNOS Inhibitors	Phase II, IIa, IIb	Migraine	Phase II data 2010
nNOS Inhibitors	Lead Series	Neuropathic pain	IND 2009
NOS Combinations	Lead Series	Rheumatoid Arthritis	IND 2009

SENIOR MANAGEMENT

Lawrence Bloch, MD, JD, Chief Executive Officer • **John Andrews, PhD**, Chief Scientific Officer

FINANCING HISTORY

Round Date (Amount, US\$): July 2004 (16.0 million) • August 2007 (32.0 million)

Investors: **Ventures West, Vancouver** • **HIG Capital, Miami** • **NeuroVentures Capital, Charlottesville** • **Genesys Capital, Toronto** • **Business Development of Canada, Toronto**

NeuroHealing Pharmaceuticals, Inc.

Neurology • CNS • Urological

Neal M. Farber, PhD
Chief Executive Officer

50 Undine Road
Newton, MA 02135
USA

www.neurohealing.com

1 (617) 965-0872

Incorporated: 2003

Ownership: Private

CORPORATE MISSION

NeuroHealing Pharmaceuticals is a development-stage company pursuing re-positioned neurologically active compounds for new specialty indications, enabled by proprietary novel formulation and drug delivery strategies. This product strategy lowers development risks and costs, while protecting pharmaceutical prices and margins. Each current product has extensive human safety data, evidence of clinical efficacy for the new indication, and clinical paths with well-defined end points.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
NH004	Phase II, IIa, IIb	Sialorrhea	Phase II completion
NH001	Phase II, IIa, IIb	Traumatic brain injury	Phase II completion
NH02D	Preclinical	Premature ejaculation	

SENIOR MANAGEMENT

Neal M. Farber, PhD, Chief Executive Officer • **Daniel Katzman**, President • **Elkan Gamzu, PhD**, Chairman • **David Gwynne, PhD**, Vice President • **Pamela Hay**, Consultant

Nupotential, Inc.

Regenerative Medicine • Gene/Cell Therapy • Metabolic Disease

Chuck Oehler

President

P.O. Box 25128
Baton Rouge, LA 70894-5128
USA

www.nupotentialinc.com

1 (225) 615-8954

Incorporated: 2007

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Second research milestone achieved, triggering second in series of \$1 million tranche payments from venture capital syndicate.

Preliminary verbal agreement for alliance providing new differentiation technology to NuPotential for development of cell therapy applications.

Alliance with Pennington Biomedical Research Center for development of multipotent cells and self renewal technologies.

Upcoming

Executed alliances to provide NuPotential with critical value-added differentiation compounds and technology that complete the value chain for developing new therapeutic cells from NuPotential's progenitor cells.

In vivo validation of efficacy of reprogramming and differentiation compounds via differentiation into new lineages valuable for therapeutic applications.

New grant funding (pending) to advance application of NuPotential's proprietary cell reprogramming platform for commercial applications (increased efficiency of cell production).

CORPORATE MISSION

NuPotential, Inc. is addressing the high-growth cell therapeutics market by developing new cell reprogramming technologies that can modify a patient's own cells to become pluripotent, or able to differentiate into any cell type. The technology will provide non-embryonic, rejection-resistant cells to develop treatments for degenerative afflictions such as diabetes, Alzheimer's, and others. NuPotential will monetize its technologies through strategic alliances with pharmaceutical, biotechnology, and related companies, which have a strong need for alternative, renewable sources of progenitor cells for cell therapy development, and through its own internal cell therapy development program.

PROPRIETARY TECHNOLOGY

NuPotential has filed multiple patents broadly covering methods to regulate the methylation status of various cellular structures such as DNA, histones, and chromatin, and thereby direct cellular reprogramming. A freedom to operate analysis completed during due diligence by independent legal counsel concluded that NuPotential has freedom to operate.

CORPORATE ALLIANCES

Pennington Biomedical Research Center, Baton Rouge, LA;

Additional alliances pending for differentiation technology, compounds and screening technologies to facilitate cell therapy development.

PRODUCTS

Name	Phase	Indication	Milestone
Pluripotent Reprogrammed Cells	Research	Multiple	In vivo validation
Clinical Cell Therapy	Research	In discussions	IND
Proprietary Cell Reprogramming Compounds	Research	Multiple	In vivo validation
Proprietary Cell Differentiation Compounds	Research	Multiple	In vivo validation

SENIOR MANAGEMENT

Chuck Oehler, President • Kenneth J. Eilertsen, Chief Scientific Officer • Rachel Power, PhD, Manager

FINANCING HISTORY

Round Date (Amount, US\$): November 2007 (3.0 million)

Oncolix, Inc.

Oncology

Michael T. Redman Chief Executive Officer

701 Grove Road
Greenville, SC 29605
USA

www.oncolixbio.com

1 (281) 923-2807

Incorporated: 2006

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Licensing of a high-yielding proprietary E coli expression system from Monsanto.

Optimization of manufacturing, including characterization, downstream processing, scale-up and vialing.

Commencement of preclinical safety and toxicology studies with anticipated completion by 4th quarter of 2009.

Upcoming

Commencement of first human trial in breast cancer patients in 4th quarter 2009.

Formal relationship with MD Anderson to help with clinical trial design.

Additional funding round of \$10 million to \$15 million.

CORPORATE MISSION

Oncolix, Inc. is focused on therapeutics for cancer, with an initial focus on breast cancer. The company's lead product, Prolanta, is in late preclinical development and is expected to enter human clinical trials in late 2009.

PROPRIETARY TECHNOLOGY

Prolanta (G129R) prevents the dimerization of the prolactin receptor (PRLR), disrupting various signaling pathways thereby suppressing breast tumor cell growth. As the PRLR is over-expressed in majority breast cancer patients, a PRL antagonist such as Prolanta serves as a novel candidate for the development of a targeted therapy for breast cancer.

CORPORATE ALLIANCES

Monsanto - Bacterial expression system and manufacturing know how.

Biovectra - Manufacturing optimization, downstream processing, scale-up and vialing.

Charles River - Master Cell Bank and preclinical safety and toxicology testing.

Greenville Hospital System - source of technology and capital investment.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Prolanta	Phase I	Breast Cancer	Phase I 4Q09

SENIOR MANAGEMENT

Michael T Redman, Chief Executive Officer • **Mitzi Montgomery, DVM, PhD**, Vice President • **Wen Chen, PhD**, Chief Scientific Officer

FINANCING HISTORY

Round Date (Amount, US\$): November 2006 (1.2 million) • January 2008 (6.0 million)

Investors: **Greenville Hospital System (66%)** • **Founding Scientists (17%)** • **Oncolix Management (17%)**

ParinGenix, Inc.

Pulmonary • Oncology

Stephen G. Marcus, MD

Chief Executive Officer

1792 Bell Tower Lane
Weston, FL 33326
USA

www.paringenix.com

1 (954) 315-3660

Incorporated: 2002

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

35 Center phase IIB 200 patient randomized placebo controlled trial in progress in acute COPD exacerbation.

Academic centers in USA, Canada, Belgium, Germany, and Poland participating.

Eligible subjects will be those with COPD who are admitted to the hospital for treatment of an acute exacerbation of their disease. All subjects will receive standard of care treatment as well as ODSH or placebo.

Upcoming

Hospitalized subjects will be studied as long as they are hospitalized as in-patients. Subjects will then be monitored as out-patients for up to three months to follow progress during recovery from exacerbation.

The primary outcome of the study, "treatment failure", will be a composite that captures both lack of improvement and early relapse.

CORPORATE MISSION

Development of non-anticoagulant heparin for inflammatory lung diseases and cancer.

PROPRIETARY TECHNOLOGY

Desulfated non-anticoagulant heparin.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
ODSH	Phase II, IIa, IIb	COPD	in 3Q09
ODSH	Phase I	Cancer	

SENIOR MANAGEMENT

Stephen G. Marcus, MD, Chief Executive Officer • **Claude Bertrand**, Chief Financial Officer • **Pedro Quintana, MD**, Chief Medical Officer
• **Teresa Arledge**, Chief Technology Officer

Profectus BioSciences, Inc.

Vaccines • Immunology

Shawn Patrick O'Brien

Chief Executive Officer

6411 Beckley Street, Suite 201
Baltimore, MD 21224
USA

www.profectusbiosciences.com

1 (866) 938-8559

Incorporated: 2005

Employees: 25

Ownership: Private

HIGHLIGHTS

Recent

Profectus and Wyeth announced an Agreement that provides Profectus a therapeutic/prophylactic vaccine program for HIV, HCV, HPV, HSV and Malaria combining proprietary technologies in the fields of pDNA and rVSV vaccines in a prime-boost strategy.

The Agreement provides Profectus with access to an extensive portfolio of intellectual property, research reagents, equipment, governmental funding, clinical trial products and a leadership team with extensive vaccines development experience.

In August, 2008 the company completed its Series B round of financing for \$8.3 million led by institutional investor, Cross Atlantic Capital Partners.

Upcoming

2Q09: Secure a research funding partner for the Malaria program via a NGO. 3Q09: Secure funding commitments for Series C.

3Q09: Submit two INDs for two of the six HIV Phase I clinical trials.

4Q09: Conduct POC animal studies with NF-kB inhibitor leads.

3Q09: Start pDNA HIV preventative vaccine trial.

4Q09: Start pDNA HIV therapeutic vaccine trial.

4Q09: Start rVSV HIV preventative vaccine trial.

CORPORATE MISSION

Profectus BioSciences, Inc. is a research and development company dedicated to harnessing the immune system to treat and prevent chronic viral diseases that lead to cancers, through the delivery of our proprietary prime/boost vaccines and small molecules. The company's name, Profectus, when translated from its Latin roots, means "to advance or improve," thus capturing the company's approach to advancing technologies to improve the health of patients suffering from chronic viral diseases.

PROPRIETARY TECHNOLOGY

Profectus recently executed an agreement with Wyeth that provides Profectus with a vaccine program for HIV, HCV, HPV, HSV and Malaria. These programs combine the Wyeth proprietary technologies in the fields of pDNA and rVSV vaccines. These products are designed to reduce the morbidity and mortality caused by chronic viral diseases.

CORPORATE ALLIANCES

Profectus BioSciences, Inc. was founded by Drs. Gallo, Blattner and Redfield in 2003 to serve, in part, as a vehicle to develop and commercialize select technologies developed at the Institute of Human Virology (IHV) and elsewhere. The company maintains a collaborative working relationship with the IHV.

PRODUCTS

Name	Phase	Indication	Milestone
Vaccine	Preclinical	HIV	Starting Phase I trials in 2009.
Vaccine	Preclinical	HCV	Secure funding to manufacture materials for clinical trials.
Vaccine	Preclinical	Malaria	Secure research funding partner
NF-kB inhibitors	Research	TBD	Conduct POC animal studies.

SENIOR MANAGEMENT

Shawn Patrick O'Brien, Chief Executive Officer • **Jeffrey Meshulam**, Business Development • **Dr. John Eldridge**, Chief Scientific Officer • **Jeffrey Stello**, Chief Financial Officer

FINANCING HISTORY

Round Date (Amount, US\$): August 2005 (5.70 million) • August 2008 (8.30 million)

Investors: **Cross Atlantic Capital Partner** (33%) • **Stewart J. Greenebaum, LLP** (22%) • **Founders, Management & Employees** (28%) • **Other** (17%)

Resolvix Pharmaceuticals, Inc.

Paul Rubin, MD

President & CEO

6A Preston Court
Bedford, MA 01730
USA

www.resolvix.com

1 (781) 541-5045

Incorporated: 2005

Employees: 27

Ownership: Private

HIGHLIGHTS

Recent

RX-10045 in phase II for dry eye.

Upcoming

RX-10001 will enter phase I in 2Q09.

CORPORATE MISSION

Resolvix Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvix's R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvix is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications.

PROPRIETARY TECHNOLOGY

Resolvins are a family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. Resolvins act to protect healthy tissue during an inflammatory response, and then resolve inflammation and promote healing. Resolvins are shown to be potent and efficacious in models of asthma, atherosclerosis, RA, IBD, dry eye and retinal diseases, among others.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
RX-10045	Phase II, IIa, IIb	Dry eye, retinal diseases	Data in mid-2009
RX-10001 (RvE1)	Phase I	Inflammatory diseases	Enter phase I in 2Q09
RX-20001 (NPD1)	Preclinical	Inflammatory diseases	

SENIOR MANAGEMENT

Paul Rubin, MD, President & CEO • **Per Gjorstrup, MD, PhD**, Chief Medical Officer • **James Nichols, PhD**, Vice President • **Lijun Wu, PhD**, Vice President • **Eric Schwartz, PhD**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$): November 2005 (17.0 million) • February 2008 (29.0 million)

Stemina Biomarker Discovery, Inc.

Drug Development • Diagnostics • Oncology

Elizabeth L.R. Donley

President & CEO

504 S. Rosa Road, Suite 150
Madison, WI 53719
USA

www.stemina.com

1 (608) 204-0104

Incorporated: 2006

Employees: 8

Ownership: Private

HIGHLIGHTS

Recent

In February 2009, Stemina and Promega Corporation announced they had entered into a collaboration agreement to improve techniques in stem cell research.

In March 2009, Stemina announced that it had completed development of its drug screening system using human embryonic stem cells to predict whether drugs, consumer products or other chemicals will cause birth defects.

In June 2008, Gabriela Cezar, DVM, PhD, Stemina's Chief Scientific Officer, was featured in Forbes Magazine as a luminary in stem cell science. Dr. Cezar is the world expert in human embryonic stem cells and metabolomics.

Upcoming

Stemina will launch its drug screening system for predicting birth defects at the 2009 Society of Toxicology meeting in Baltimore, Maryland.

Stemina will begin a human clinical trial to identify the biomarkers of cancer stem cells it has discovered in patient samples.

Stemina will begin raising a second round of funding in the 2Q09.

CORPORATE MISSION

Stemina Biomarker Discovery, Inc. is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Stemina's cell based assays arise from the strategic convergence of two cutting edge technologies: stem cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by human embryonic stem (hES) cells, differentiated cells such as heart and neural cells made from hES cells, and cancer stem cells in response to drugs, injury or disease. These small molecules secreted in response to injury or disease are then translated into diagnostic biomarkers in patient samples.

PROPRIETARY TECHNOLOGY

Stemina uses hES cells to screen compounds for the potential to cause birth defects. Stemina has also discovered biomarkers of cancer stem cells. These biomarkers will be used to screen cancer therapies for their effectiveness in killing cancer stem cells. These biomarkers may also be used to diagnose the presence of cancer stem cells in patients and to monitor patient response to therapy.

CORPORATE ALLIANCES

Stemina has entered into or is currently negotiating agreements with organizations including Promega, Pfizer, Cellartis, SAFC, Quintessence BioScience, Mayo Clinic, WARF and the University of Wisconsin.

PRODUCTS

Name	Phase	Indication	Milestone
DevTox Assay	Other	Screen for birth defects	Service Launched
Biomarkers of Cancer Stem Cells	Research	Screen for efficacy of cancer therapies	Biomarkers Identified
Biomarkers of Cancer Stem Cells	Research	Diagnostic	Clinical Trial Planning
Biomarkers of Cardiomyopathies	Research	Diagnostic	Planning
CardioTox Assay	Research	Screen for cardiotoxicity	Biomarkers identified

SENIOR MANAGEMENT

Elizabeth L.R. Donley, President & CEO • Gabriela G. Cezar, Chief Scientific Officer • Paul R. West, Other

FINANCING HISTORY

Round Date (Amount, US\$): November 2007 (1.6 million) • May 2007 (1.0 million)

Investors: Elizabeth L.R. Donley (30%) • Gabriela G. Cezar (30%) • Angel Groups (10%) • Individual Investors (30%)

Targepeutics, Inc.

Oncology

Sil Lutkewitte

President & CEO

475 West Governor Road
Hershey, PA 17033
USA

www.targepeutics.com

1 (717) 533-7772

Incorporated: 1997

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

Completed GLP manufacture of lead compound in commercially viable quantities. Prepared to transfer to cGMP facility upon funding.

Recruited experienced management and development team with the requisite clinical experience in developing cancer compounds.

Completed independent analysis of potential effect of lead compound on prostate cancer.

Upcoming

Complete development of GB-13 consistent with plan reviewed by FDA in pre-IND meeting already held.

file IND and begin PI trial in brain cancer.

Define clinical and regulatory pathway for the use of GB-13 in prostate cancer, and begin preclinical testing for this indication.

CORPORATE MISSION

The mission of Targepeutics is to become a leading bio-pharmaceutical company specializing in targeting disease restricted biomarkers with molecular therapeutics and imaging agents.

PROPRIETARY TECHNOLOGY

Targepeutics' lead technology platform specifically targets the tumor restricted IL13Ra2, but not the physiologically abundant IL13Ra1. This is accomplished by changing the normal IL13 molecule in specific locations to abrogate its binding to the physiological IL13Ra1 while simultaneously increasing its affinity towards the tumor-restricted IL13Ra2.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
GB13	Preclinical	Brain & prostate cancer
Tri-Exo	Research	Cancer
Tri-alphaScint	Research	Cancer
Tri-alphaRIT	Research	Cancer

SENIOR MANAGEMENT

Sil Lutkewitte, President & CEO

Tetraphase Pharmaceuticals, Inc.

Infectious Disease • Drug Discovery • Drug Development

Guy Macdonald

President & CEO

480 Arsenal Street, Suite 110
Watertown, MA 02472
USA

www.tphase.com

1 (617) 715-3600

Incorporated: 2006

Employees: 22

Ownership: Private

HIGHLIGHTS

Recent

Completion of GLP toxicology for broad spectrum antibiotic IND candidate, TP-434.

The company recently synthesized its 900th novel tetracycline derivative.

Upcoming

Close series B round of financing in 2Q09.

Initiate first-in-human trial with TP-434 in 3Q09.

CORPORATE MISSION

Capitalizing on breakthrough synthetic chemistry pioneered at Harvard, Tetraphase Pharmaceuticals has created a highly productive and proprietary drug discovery engine targeted at several significant disease categories. The company's mission is to fully exploit this uniquely powerful platform and become a leader in the creation of fully synthetic novel tetracyclines and related compounds to address major unmet medical need in infectious and other diseases.

PROPRIETARY TECHNOLOGY

The Tetraphase technology platform is based on a ground-breaking, fully synthetic method of generating novel tetracycline derivatives. The ability to explore previously inaccessible structural variations has led to the creation of diverse, novel and potent compounds. The company has produced and profiled hundreds of such compounds, some of which have highly attractive antibacterial properties.

CORPORATE ALLIANCES

Tetraphase's programs are currently unpartnered.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
TP-434	Preclinical	Bacterial infection	IND filing late 2Q09

SENIOR MANAGEMENT

Guy Macdonald, President & CEO • **Louis Plamondon, PhD**, Chief Scientific Officer • **David Lubner**, Other • **Xiao-Yi Xiao, PhD**, Vice President • **Leland Webster, PhD, MBA**, Business Development

Teva Pharmaceuticals USA, Inc.

Oncology • Neurology • Autoimmune

William Marth

President & CEO (TEVA North America)

2 University Plaza, Ste. 305
Hackensack, NJ 07601
USA

www.tevapartners.com

1 (201) 286-9242

Incorporated: 1944
Employees: 15,000
Ownership: Public
NASDAQ: TEVA

CORPORATE MISSION

Teva Pharmaceuticals is the world's largest generic manufacturer. Teva Innovative Ventures, the innovative side of Teva, is actively looking to in-license pre-clinical opportunities in our current therapeutic focus areas (Neurology, Autoimmune/ Inflammation, Oncology) as well as additional specialty areas (products marketed to medical specialists) that have the following attributes:

- New chemical/biological entities with strong IP.
- Satisfy high unmet medical need.
- Demonstrated in-vivo pharmacological proof of concept.
- Potential advantages over existing drugs.

Topaz Pharmaceuticals, Inc.

Drug Development • Skin/Dermatological • Infectious Disease

Nicholas U. Spring Chief Executive Officer

100 Witmer Road
Horsham, PA 19044
USA

www.topazpharma.com

1 (267) 960-3330

Incorporated: 2005

Ownership: Private

HIGHLIGHTS

Recent

Series A funding.

CORPORATE MISSION

Topaz Pharmaceuticals, Inc. is dedicated to the research, development and marketing of new and existing pharmaceuticals that keep kids healthy.

PROPRIETARY TECHNOLOGY

Topaz has developed a proprietary technology to fill a market need for a safe, effective, proven, prescription head lice treatment.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>
TBC	Phase II, IIa, IIb	Head lice

SENIOR MANAGEMENT

Nicholas U. Spring, Chief Executive Officer • **Reid S. McCarthy**, Chief Financial Officer

FINANCING HISTORY

Round Date (Amount, US\$): June 2006 (4.20 million)

TyrogeneX

Oncology • Biopharmaceuticals • Drug Development

Sheridan G. Snyder

President & CEO

501 South Flagler Drive, Suite 501
West Palm Beach, FL 33401
USA

www.biocati.com

1 (561) 659-1945

Incorporated: 2006

Employees: 4

Ownership: Private

CORPORATE MISSION

TyrogeneX has developed X-82, a novel oral multi-kinase inhibitor for the treatment of solid tumors. The compound is designed to enhance radiation therapy and has demonstrated efficacy to treat macular degeneration. Completed pre-clinical testing has shown that X-82 demonstrates high efficacy with very low toxicity.

TyrogeneX is currently seeking a \$5 million Series A financing round to take X-82 through Phase I clinical trials.

PROPRIETARY TECHNOLOGY

X-82 is a novel oral multi-kinase angiogenesis inhibitor. As such, it acts to disrupt the supply of blood, nutrients, and oxygen, effectively starving the tumor(s). Supporting published research indicates that VEGFR and PDGFR combined inhibitors destroy the growth of primary cancer tumors and target the mechanisms of cell proliferation and metastases.

CORPORATE ALLIANCES

TyrogeneX is a BioCatalyst International portfolio company.

BioCatalyst is led by Sheridan Snyder, a 42 year start-up veteran whose past companies include Genzyme (1981), Biotage (1991), Upstate (1996) and MolecularMD (2006).

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
X-82	Preclinical	Solid tumors	Filing of IND in 3Q09

SENIOR MANAGEMENT

Sheridan G. Snyder, President & CEO • **Chris Liang, PhD**, Chief Scientific Officer

Viron Therapeutics, Inc.

Immunology • Biopharmaceuticals • AutoImmune

James M. Rae President & CEO

700 Collip Circle
Suite 203
London, ON N6G 4X8
Canada

www.vironinc.com

1 (519) 858-5120

Incorporated: 1998

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Currently Preparing Phase IIa data for publication and public release.
Head-to-head data demonstrating VT-346's (anti-TNF) superior potency compared to all three marketed anti-TNF therapies.

Upcoming

Final report of Phase IIa clinical study.
Filing of an IND for solid organ transplantation (VT-111).
GMP manufacturing of VT-346 to support IND enabling toxicology.

CORPORATE MISSION

Viron Therapeutics is a privately held, Phase II clinical stage company developing a completely novel class of protein therapeutics targeting inflammatory diseases such as transplant, vascular disease, RA and IBD. In the same way that fungi have evolved to produce antibiotics, viruses have evolved to produce anti-inflammatory proteins. By identifying these proteins and their mechanisms of action, Viron has built a proprietary portfolio of promising therapeutic candidates that act to neutralize numerous key pro-inflammatory pathways. Viron has a strong pipeline of proprietary and novel drug candidates, comprised of 1 clinical, 4 preclinical and several early discovery compounds. With data analysis underway for our Phase IIa clinical trial, Viron is the only company to date that has advanced into human clinical trials with this powerful new class of protein therapeutics and is poised to become a leader in the treatment of inflammatory disease.

PROPRIETARY TECHNOLOGY

In the same way that fungi have evolved to produce antibiotics, viruses have evolved to produce some of the most potent anti-inflammatory proteins ever described. Viron has built a proprietary portfolio of promising therapeutic candidates that act to neutralize numerous key pro-inflammatory pathways associated with various inflammatory and autoimmune diseases.

CORPORATE ALLIANCES

Viron is in discussions with potential development partners for its lead and pipeline drug candidates. It also enjoys numerous alliances with academic institutions around the world.

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
VT-111	Phase II, IIa, IIb	Vascular Inflammation - ACS	Completion of Ph II trial
VT-111	Preclinical	Chronic Transplant Rejection	Initiation of Phase I
VT-346	Preclinical	Rheumatoid Arthritis/Psoriasis	IND approval
VT-214	Preclinical	Autoimmune	lead indication selection
VT-384	Preclinical	RA	Proof of Concept Data
VT-310	Preclinical	Autoimmune	Animal efficacy

SENIOR MANAGEMENT

James M. Rae, President & CEO • **Rob Browne**, Chief Financial Officer • **Dr. Colin Macaulay**, Other • **Kevin Sullivan**, Business Dev.

FINANCING HISTORY

Round Date (Amount, US\$): June 2006 (20.0 million)

Investors: **Novartis Pharma AG** • **Amgen Ventures, LLC** • **Business Development Bank of Canada** • **GrowthWorks Capital** • **Fairway Capital**

Vitreoretinal Technologies, Inc.

Biopharmaceuticals • Ophthalmic • Metabolic Disease

Hampar Karageozian

Chief Technology Officer

2 Venture, Suite 430
Irvine, CA 92618
USA

www.vrtco.com

1 (949) 753-1008

Incorporated: 2000

Employees: 9

Ownership: Private

HIGHLIGHTS

Recent

Initiated two Phase III clinical trials for vitreosolve.

A total of 160 plus subjects have been enrolled in these two studies.

We plan to submit NDA for this drug candidate by 4Q11.

Neurosolve has been granted an orphan status for retinitis pigmentosa.

Neurosolve has been granted a Phase III designation for glaucoma.

CORPORATE MISSION

Vitreoretinal Technologies, Inc., (VRT) is a biopharmaceutical Company dedicated to address significant unmet needs in ophthalmic disease. VRT's products will be well positioned to serve the fast-growing specialty pharmaceutical markets related to aging when regulatory approval is received. VRT's products will treat ophthalmic conditions that affect large patient populations, creating a substantial market and revenue potential.

VRT's unique strength has been to carry its product development efforts through early stages, utilizing its network of clinical professionals around the world in the most cost-effective manner. Vitreosolve® is in late stages of development and data from completed studies suggest it to be safe and effective in humans.

PROPRIETARY TECHNOLOGY

Vitreosolve® prevents the progression of diabetic retinopathy to a proliferative stage that requires surgical intervention. Few intravitreal treatments of the drug will induce a gradual, atraumatic and permanent anatomical effect that prevents the progression of the disease a proliferative stage.

PRODUCTS

Name	Phase	Indication	Milestone
Vitreosolve	Phase III	Diabetic retinopathy	Completion of first pivotal study in April 2010
Neurosolve	Phase II, IIa, IIb	glaucoma and retinitis pigmentosa	

SENIOR MANAGEMENT

Hampar Karageozian, Chief Technology Officer • Ramgopal Rao, Chief Business Officer • Vicken Karageozian, Chief Medical Officer

FINANCING HISTORY

Round Date (Amount, US\$): June 2007 (9.9 million)